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Glioblastoma multiforme (GBM) is an aggressive cancer that affects millions of 
patients per year.  Conventional therapies combining chemotherapeutic agents with 
radiation can only extend survival by a few months; therefore, there is a dire need for an 
effective means of treating this deadly disease.  Melanoma differentiation-associated gene-
7/interleukin-24 (mda-7/IL-24), currently in the early stages of FDA pre-IND drug trials, 
has proven to be an effective cancer specific cytokine, able to trigger the onset of 
mitochondrial dysfunction and/or autophagy.  GBM’s have mutations that often result in 
the activation of cytoprotective cell signaling pathways, preventing cancer therapeutics and 
even MDA-7/IL-24 treatments from being effective.  Since the discovery of MDA-7/IL-24 
a number of groups have shown toxic effects in a variety of tumor cells. However, the 
lethality of MDA-7/IL-24 is not enough to eradicate the tumor.  We hypothesized two 
xxiii 
rationales for this minimalistic effect.  First, the MDA-7/IL-24 gene delivery mechanisms 
are not efficient or second, active pro-survival pathways are playing a role in protection. 
Here we have shown that the inhibition of cytoprotective cell-signaling pathways using 
small molecule inhibitors of mitogen-activated extracellular regulated kinase (MEK)1/2  
and phosphatidyl inositol 3-kinase (PI3K) or AKT; mammalian target of rapamycin 
(mTOR) and MEK1/2; HSP90 inhibitor 17AAG; and the autophagy-inducing drug OSU-
03012 (AR-12),  enhances the toxicity of MDA-7/IL-24.  In addition, the use of a modified 
recombinant adenovirus comprised of the tail and shaft domains of a serotype 5 virus and 
the knob domain of a serotype 3 virus expressing MDA-7/IL-24, Ad.5/3-mda-7,  proved to 
be a more effective, CAR-independent  means of infecting and killing GBM cells in vitro 
and in vivo when compared to Ad.5-mda-7. Collectively, our data demonstrate that the 
induction of autophagy and mitochondrial dysfunction by a combinatorial treatment 
approach represents a potentially viable strategy to kill primary human GBM cells. 
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CHAPTER 1 INTRODUCTION: GENERAL 
 
 
1.1 Cancer:   
Cancer (malignant neoplasm), is a group of diseases that stems from the unrestrained 
cell division of normal cells originating from almost any organ or tissue in the body.  
Under normal circumstances, cells are highly regulated by signaling processes necessary 
for the proper control of growth or death.  A loss in this functionality can lead a normal 
cell to exhibit one of six recognized characteristics of a cancer cell.  “The Hallmarks” of a 
cancer cell include: overactive cell proliferation signaling, loss of contact inhibition, 
resistance to cell death, resistance to growth suppressors and metastatic potential.  On a 
daily basis, a normal cell is stressed to a certain degree by both internal (inherited 
mutations, hormones and immune conditions) and external factors (tobacco, infectious 
organisms, chemicals and radiation) potentially acting together to dsyregulate the cells 
protective signaling machinery, promoting carcinogenesis.
1
  This explains the staggering 
statistics presented this year by the National Cancer Institute; were nearly one-quarter of 
deaths occurring due to disease in the United States are cancer related, exceeded only by 
heart disease.  Since 2008, cancer has been the leading cause of death worldwide, claiming 
the lives of over 7 million people.
2
  
 
2 
 
 
1.2 Glioblastoma multiforme: 
Globally, glioblastoma multiforme (GBM) often found in the posterior cranial fossa in 
children or the anterior two-thirds of the cerebrum in adults, is the most common and lethal 
malignant primary brain cancer, diagnosed in over 125,000 patients and claiming the lives 
of over 95,000 patients per year.
2
  Even under optimal conditions, where essentially all of 
the tumor can be surgically removed and the patients maximally treated with radiation and 
chemotherapy, the mean survival of this disease is extended from a few months to one 
year, with a 5 year survival rate of only 5%.
3
 The main reason for this poor prognosis is to 
the ability of GBM to invade brain tissue and to inherently develop drug resistance.  Drug 
resistance has been shown by many groups to be due to, but not limited to, drug efflux, 
hypoxia, cancer stem cells, DNA damage repair machinery and miRNA’s.  In addition, 
much like all other cancers, GBMs have mutations that further enable their survival. For 
example, GBM6 cells contain a mutant variant III EGFR (Epidermal Growth Factor 
Receptor).  This mutation has been shown to stimulate mTORC2 activity which in turn 
promotes NF-κB activity promoting cell growth, survival and resistance to chemotherapy.  
GBM14 cells contain a mutation that prevents the production of PTEN, a protein necessary 
for the inactivation of the pro-survival and growth signaling cascades involving 
AKT/mTOR.  GBM12 cells possess a mutant active full-length EGFR. In this situation, the 
receptor, a tyrosine kinase receptor involved in the activation of the Raf/MEK/Erk 
signaling cascade is in a constant active state, leading to promotion of growth and survival 
3 
of these cancer cells.
4,5
  Following surgery or drug treatment, the loss of inhibitory control 
and cross-talk of signaling pathways prevent the efficacy of cancer therapeutics and result 
in the return of a more invasive and aggressive cancer growth. These realities emphasize 
the need to further advance therapeutic intervention or create more effective modalities to 
combat this devastating and consistently fatal disease. 
 
1.3 Conventional Treatments:   
Various treatments for cancer exist, each dependent upon the type and/or stage of the 
cancer.  Treatment options for GBM include:  
1.  Surgery (removal of the tumor) via craniotomy, is not always possible if access 
to the tumor is impeded or if the cancer has metastasized.  
2.  Radiation therapy (also called irradiation) in which ionizing radiation is used to 
kill cancer cells and shrink the tumor. The effects of radiation therapy are not 
localized and/or confined to only the tumor.  Ionizing radiation damages the genetic 
material of a cell by way of dislodging electrons from atoms impacted by it; 
generating damaging ions within the cells.  Unfortunately, it will also damage the 
DNA of healthy cells; this is the reason why radiation is given in small fractions to 
allow for damaged non-tumor cells time to recover proper functionality.   
3. Chemotherapy, treatment with drugs that can destroy cancer cells. This term 
refers to cytotoxic drugs which affect rapidly dividing cells but are not specific for 
cancer cells, also harming healthy tissue.  More recently, specific targeting 
4 
chemotherapeutic agents are being sought after to reduce the unwanted side-effects 
to this effective mode of tumor cell killing, such as Temazolomide (TMZ).
6
  
4.  Combination Therapy; combining drugs that have different modes of action and 
different toxicities.  One advantage of combination therapy is that it may delay or 
prevent drug resistance.
1
 Another advantage lies in obtaining synergistic killing of 
tumor cells, with minimal exposure to treatments such as radiation and/or 
chemotherapeutic agents; ultimately, reducing the presently observed side effects of 
conventional therapies.   
 
1.4 Gene Therapy and MDA-7/IL-24 
The advent of gene therapy has proven partially successful for the treatment of 
tumor cells.  Recombinant viruses containing specific gene modulating properties, such as 
tumor suppressor genes or genes involved in production of toxic cytokines, have shown to 
be partially effective in reducing tumor cell growth and survival.
7
  Other modestly 
succesful approaches include the use of modified forms of adenoviruses that are selectively 
replicative and initiate their lytic cycles only when found within a tumor cell and not in 
normal non-transformed cells.
8
 Thus although promising, gene therapy has yet to truly 
make an significant impact in cancer therapy.   
The mda-7 gene (recently renamed Interleukin 24, IL-24) was isolated from human 
melanoma cells induced to undergo terminal differentiation by treatment with fibroblast 
interferon and mezerein.
9
 The RNA and protein expression of MDA-7/IL-24, a member of 
the interleukin-10 (IL-10) gene family,
10,15-18, 22-26
 is decreased in advanced melanomas, 
5 
with nearly undetectable levels in metastatic disease.
27-29
 Enforced expression of MDA-
7/IL-24, in tumor cells, by use of a recombinant adenovirus Ad.mda-7, inhibits growth and 
kills a broad spectrum of cancer cells, without exerting any harmful effects in normal 
human epithelial or fibroblast cells.
14-18,22,23
 In view of the potent cancer-specific, 
apoptosis-inducing and tumor growth-suppressing properties of MDA-7/IL-24 in human 
tumor xenograft animal models, mda-7/IL-24 has been evaluated in a Phase I clinical trial 
in patients with advanced cancers.
15,16,18,24-26
 This study indicated that Ad.mda-7 injected 
intra-tumorally was safe and with repeated injection, manifested noteworthy clinical 
activity in 44% of the treated patients. This is particularly notable because the patients in 
this trial had already been exposed to multiple different chemotherapies and would be 
predicted to have a high inherent level of resistance to any additional therapeutic.  
The apoptotic pathways by which Ad.mda-7 leads to cell death in tumor cells are 
not fully understood. However, current data suggests an intrinsic complexity and a 
contribution of proteins central for the onset of growth inhibition and apoptosis, including 
BCL-XL BCL-2 and BAX.
14-18,22,23
 In human melanoma cell lines, but not in normal 
melanocytes, Ad.mda-7 infection induces a significant decrease in both BCL-2 and BCL-
XL levels, with only a modest up regulation of BAX and BAK expression.
27
 This data 
supports the hypothesis that Ad.mda-7 increases the ratio of pro-apoptotic to anti-apoptotic 
proteins in cancer cells, thereby facilitating induction of apoptosis.
15-18,22,23,27
 The ability of 
Ad.mda-7 to promote apoptosis in DU-145 prostate cancer cells, which do not produce 
BAX, indicates that MDA-7/IL-24 can initiate apoptosis in tumor cells through a BAX-
independent pathway.
15-18,22
 In prostate cancer cells, overexpression of either BCL-2 or 
6 
BCL-XL protects cells from Ad.mda-7-induced toxicity in a cell type-dependent fashion.
28
 
In a single ovarian cancer cell line, MDA-7/IL24 was reported to kill via the extrinsic 
apoptosis pathway.
29
 Accordingly, MDA-7/IL-24 toxicity appears to occur by multiple 
distinct pathways in different cell types, but in all of these studies cell killing is associated 
with a profound induction of mitochondrial dysfunction.
30
  
More recently, MDA-7/IL-24 toxicity has been coupled with alterations in 
endoplasmic reticulum stress signaling.
31
 In these studies; MDA-7/IL-24 physically 
associates with BiP/GRP78 and nullifies the protective actions of this ER-chaperone 
protein. In addition to virus-administered mda-7/IL-24, cancer-specific killing is retained 
by delivery of this cytokine as a bacterially expressed GST fusion protein, GST-MDA-7.
32
 
In addition, selective ER localization and similar signal transduction changes in cancer 
cells is also seen.
31
 We have found that a high concentration of GST-MDA-7 kills primary 
human glioma cells and does so in a PERK-dependent fashion that is dependent upon 
elevated levels of autophagy and mitochondrial dysfunction.
34-36
  
The ability of MDA-7/IL-24 to modulate cell-signaling processes in transformed 
cells has been examined by several laboratories.
22-40
 Prior work by our group has shown, 
using bacterially synthesized GST-MDA-7 protein,
32
 that in the 0.25– 2.0 nM 
concentration range GST-MDA-7 primarily produces growth arrest with minimal cell 
killing. Whereas, at ∼20-fold greater concentrations, this cytokine causes profound growth 
arrest and tumor cell death.
32,35,36
 Our group have also demonstrated that Ad.mda-7 kills 
melanoma cells in part by promoting p38 MAPK-dependent activation of growth arrest 
and DNA damage inducible genes, including GADD153, GADD45 and GADD34.
38
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However, in primary GBM cells, it was noted that p38 MAPK signaling provided a 
protective signal.28 Other groups have argued that inhibition of PI3K signaling, but not 
ERK1/2 signaling, modestly promotes Ad.mda-7 lethality in breast and lung cancer 
cells.
39,40
  (Figure 1.1 and 1.2) 
 
 
 
 
Figure 1.1 – Signaling pathways associated with Ad. mda-7 and MDA-7/IL-24 activity.17 
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Figure 1.2 – Signaling pathways associated with MDA-7/IL-24.154  
Although promising, the delivery of therapeutic genes using a serotype 5 (Ad.5) virus 
vector has shown limitations in treating GBMs. This limited potential is due to the 
dependence of the adenoviruses on expression of the Coxsackie adenovirus receptor 
(CARs) for virus entry.   Multiple groups have shown that the use of a tropism-modified 
adenovirus that e.g. uses a serotype 3 modification of the viral knob protein, can better 
facilitate the delivery of mda-7/IL-24 in a CAR-independent manner (Ad.5/3 vector).
41,42
  
A tropism modification, may provide a means of developing an improved therapy for 
GBM, a currently consistently fatal cancer. 
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1.5 Raf/MEK/ERK Mitogen-activated protein kinase (MAP) pathway 
 Targeted-based therapies are considered to be the future of cancer treatment and 
much attention has been focused on the development of inhibitors of the Raf/MEK/ERK 
MAP kinase pathway.  The Raf/MEK/ERK MAP kinase pathway is commonly 
dysregulated in cancer cells.
43-45
  There are four well characterized MAPKs.  Each cascade 
consists of three proteins that act as a relay mainly by phosphorylation signaling.  There is 
a MAPK kinase kinase (MAPKKK, MAP3K), a MAPK kinase (MAPKK, MAP2K), and a 
MAPK.  The terminal serine/threonine kinases (MAPKS) comprises, ERK1/2, c-Jun NH2-
terminal kinase (JNK1/2), p38, and ERK5 (Figure 1.3).  Activation of the ERK1/2 pathway 
is often associated with cell survival, whereas JNK, p38, and ERK5 are activated by stress 
and growth factors.
45,46
 Although the mechanisms by which ERK1/2 activation promote 
survival are not fully characterized, a number of anti-apoptotic effector proteins have been 
identified, including increased expression of anti-apoptotic proteins such as c-FLIP, Bcl-
xL, XIAP, and Mcl-1.
44,47-51
 
 In the ERK MAPK module, Ras is a small GTP-binding protein which acts as the 
molecular switch that controls this signaling pathway. There are four Ras proteins, namely 
H-Ras, N-Ras, Ki-Ras 4A and Ki-Ras4B.  Ras is mutationally activated in a variety of 
cancers, though not in GBM, and this leads to persistent activation of downstream 
effectors.
52
   In normal quiescent cells, Ras is inactivated (GDP-bound). Extracellular 
stimuli (i.e. EGF), induce the exchange of guanosine diphosphate (GDP) for guanosine 
triphosphate (GTP) which converts Ras into its active conformation. In many tumors that 
express wild type Ras proteins, the wild type protein is often constitutively active due to 
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the upstream actions of receptor tyrosine kinases e.g. expression of EGFR vIII.  This 
process relies on the recruitment of GDP/GTP exchange factors to the cell membrane.  
Guanine nucleotide exchange factors (GEFs; i.e. Sons of Sevenless, SOS) promote 
formation of active Ras-GTP, whereas GTP activating proteins (GAPS) stimulate GTP 
hydrolysis and formation of inactive Ras-GDP.
45
    Ras activation leads to the recruitment 
and activation of the MAPKKK (MAP3K), Raf serine/threonine kinases (c-Raf-1, B-Raf, 
and A-Raf).  Activation of Raf kinases is a multistep process that involves 
dephosphorylation of inhibitor sites by protein phosphatases 2A (PP2A) as well as 
phosphorylation of activating sites by PAK (p21 activated kinase).  The regulatory 
mechanisms of various isoforms differ in that A-Raf and C-Raf-1 require additional 
phosphorylation reactions for activity whereas B-Raf has a much higher level of basal 
kinase activity. B-Raf is mutated in many cancers making it constitutively active.
45
 Raf 
kinases phosphorylate and activate MAPKKs, MEK1/2.  MEK1/2 then phosphorylates and 
activates ERK1/2 MAPKs.
53,54
  Active ERKs phosphorylate numerous cytoplasmic and 
nuclear targets regulating processes such as proliferation, differentiation, and survival 
(Figure 1.4).
45
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Figure 1.3. Mammalian MAPK cascades.  There are four major mammalian protein 
kinase cascades; each consists of a MAPKKK, MAPKK, and MAPK.  The ERK1/2 
pathway is the activated by growth factors, whereas the JNK and p38 pathways are 
activated by environmental stressors such as ionizing radiation.
45
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Figure 1.4.  Activation of the Raf/MEK/ERK Mitogen-activated protein kinase 
(MAP) pathway.  The binding of a growth factor to a growth factor receptor induces 
receptor dimerization and autophosphorylation on tyrosine residues.  These phospho-
tyrosines are docking sites for signaling molecules which include Grb2-SOS complex.  
This complex activates the small G-protein Ras by stimulating the exchange of guanosine 
diphsophate (GDP) for guanosine triphosphate (GTP).  Ras undergoes a conformational 
change which enables it to recruit Raf-1 from the cytosol to the cell membrane and bind to 
it where Raf-1 becomes active.  Activated Raf-1 phosphorylates and activates MEK1/2 
which in turn will phosphorylate and activate ERK1/2.  Activated ERK may translocate to 
the nucleus to control gene expression of transcription factors promoting growth, 
differentiation, and cellular development.
45,53,55
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1.6 JNK1/2 MAPK Pathway 
 
 JNK1/2 pathway signaling often causes apoptosis.  JNK activation is much more 
complex than that of the ERK1/2 pathway owing to inputs by a greater number of 
MAPKKKs  (at least 13, including MEKK1 (MAP/ERK Kinase-Kinase-1)-MEKK4 
(MAP/ERK Kinase-Kinase-4), ASK (Apoptosis Signal-regulating Kinase), and MLKs 
(Mixed-Lineage Kinases), which are activated by upstream Rho-family GTPases. These 
phosphorylate and activate MAPKKs MEK4 (MAPK/ERK Kinase-4) and MEK7 
(MAPK/ERK Kinase-7),which further phosphorylate and activate JNKs.  JNK activation 
requires dual phosphorylation of tyrosine and threonine residues.  The JNK family consists 
of JNK 1, 2, and 3 (also known as SAPKγ, SAPKα, and SAPKβ, respectively).   JNK 1 
and 2 are ubiquitously expressed, whereas JNK 3 is restricted to the brain, heart, and 
testis.
56
 
 JNKs (MAPKs) are primarily activated in response to cytokines, UV irradiation, 
DNA-damaging agents, growth factor deprivation, and to a lesser extent, serum, and G-
protein coupled receptors.  The JNKs are able to translocate to the nucleus following 
stimulation. JNKs are generally thought to be involved in inflammation, proliferation and 
apoptosis. Accordingly, its substrates are transcription factors and pro- and anti-apoptotic 
proteins.  One well known substrate of JNK is the transcription factor c-Jun.  Others 
include Elk1, p53, ATF2 (Activating Transcription Factor-2), NFAT4 (Nuclear Factor of 
Activated T-Cell-4), and NFAT1 (Nuclear Factor of Activated T-Cell-1) . JNK mediates 
apoptosis not only through its effects on gene transcription, but also through a 
transcriptional-independent mechanism. For example, JNK1 directly phosphorylates Bcl-2 
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(B-Cell CLL/Lymphoma-2) in vitro, co-localizes and collaborates with Bcl-2 to mediate 
cell death.  JNK can also phosphorylate the pro-apoptotic protein Bim and Bmf to promote 
their pro-apoptotic effects.
57
 JNK cascade can also phosphorylate and activate  HSF1 (Heat 
Shock Factor-1) and JNK-mediated phosphorylation of HSF1 selectively stabilizes the  
HSF1 protein and confers protection to cells under conditions of severe stress.
45
  Thus, 
JNKs have opposing roles in promoting proliferation and transformation and inducing 
apoptosis.   
 
1.7 p38 MAPK Pathway 
  In a similar manner to that of the JNK1/2 pathway, the p38 MAPK pathway is 
activated by numerous cellular stresses.  The p38 module consists of several MAPKKKs; 
these include TAK1, ASK1/2, DLK, MEKK1-4, MLK2 and -3, and Tpl-2.  The 
MAPKKKS phosphorylate and activate MAPKKs, MEK3 and MEK6.  These MAPKKs 
show a high degree of specificity toward p38 as they do not activate JNK or ERK1/2.  
MEK4 however, activates both JNK and p38 and can thus be seen as a site of integration 
for the p38 and JNK pathways.
45
 The MAPKKs phosphorylate and activate MAPK p38 
pathyway. There are four isoforms of p38, α, β, γ, and δ.  p38α and p38β are ubiquitously 
expressed while p38γ and p38δ are differentially expressed in certain tissues.  All p38 
kinases have dual phosphorylation sites. MEK6 activates all p38 isoforms, but MEK3 
selectively phosphorylates the p38 α and p38β isoforms.58   
  The p38 MAPK pathway has a diverse role in the signaling of cellular responses 
that varies with cell type and stimulus. Transcription factors that regulate inflammatory 
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gene expression are phosphorylated and activated by p38 A protein kinase termed MAP 
kinase-activated protein kinase 2 (MAPKAP2) is phosphorylated by p38 and is also 
involved in many cellular processes including stress and inflammatory responses, nuclear 
export, gene expression regulation and cell proliferation.   Heat shock protein HSP27 (a 
chaperone) was shown to be one of the substrates of this kinase in vivo.  Other substrates 
of p38 include p53, involved in tumor suppression and cell cycle regulators such as 
CDC25A, B, and C.  p38 has also been implicated in other cellular responses such as cell 
death, development, and cell differentiation.
59
      
 
1.8 PI3-Kinase/Akt Pathway 
  The phosphatidylinositol 3’-kinase (PI3-K)/ Akt signaling is regarded as a pro-
survival pathway in cells.  PI3Ks are a family of intracellular lipid kinases that 
phosphorylate the 3’-hydroxyl group of phosphatidylinositols and phosphoinositides.  
PI3Ks are heterodimeric kinases that are composed of a regulatory and catalytic subunit 
that are encoded by different genes.  PI3Ks are classified into three groups, class I, II, and 
III based on structure and function.
60
   
Class I PI3Ks phosphorylate the lipid phosphatidylinositol 4, 5, bisphosphate (PIP2) 
to generate the second messenger phosphatidylinositol 3, 4, 5, trisphosphate (PIP3).  The 
class I PI3Ks can be further subdivided according to the signaling receptors that activate 
them. Class IA PI3Ks are activated by growth factor receptor tyrosine kinases (RTKs), and 
class IIB PI3Ks are activated by G-protein coupled receptors (GPCRs).  The regulatory 
subunit of class IA is p85 (with three isoforms:  p85α, p85β, p55γ). The catalytic subunit 
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of class IA is p110 (also with three isoforms: α, β, γ). Class IB members consist of a p101 
regulatory subunit and a p110γ catalytic subunit.60  Class II and class III PI3Ks 
phosphorylate phosphatidylinositol (PI) to generate PIP3.  Class II PI3Ks bind clathrin 
coated pits and may function in membrane trafficking or receptor internalization.
61
 VPS34 
is the only mammalian class III PI3K and acts as a sensor signaling to mammalian target of 
rapamycin (mTOR) to regulate cell growth and autophagy in response to low nutrient 
pools.
62
 Class IA however, is the only PI3K class that has been demonstrated to be clearly 
involved in oncogenesis.
60
  
 Upon ligand binding to RTKs, RTKs dimerize and autophosphorylate at tyrosine 
residues.  This allows them to interact with Src homology 2 (SH2) domain containing 
molecules.  PI3K can be activated by three independent pathways.  In one activation 
pathway, PI3K p85 regulatory subunit binds directly to tyrosine motifs within the RTK 
triggering activation of PI3Ks catalytic subunit. Another pathway consists of the adapter 
protein GRB2 which binds preferentially to phosphotyrosine motifs in the RTK.  GRB2 
can bind to the scaffolding protein GAB (GRB2-asssociated binding protein), which can 
bind to p85.  GRB2 can also bind to SOS and activate RAS.  RAS can activate p110 
independently of p85.
63
 When PI3K is activated it results in the generation of PIP3.  3’-
phosphoinositide dependent kinase 1 (PDK1) and Akt preferentially bind to PIP3 (by 
recruitment to the membrane) which lead to Akt activation depending on its 
phosphorylation at Ser473 or Thr308 sites by PDK1.  Phosphatase tensin homolog 
(PTEN), a protein frequently absent in GBM cells, is a negative regulator of PI3-K 
pathway that converts PIP3 back to PIP2.
5,60,63
  Akt (also known as protein kinase B, PKB) 
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phosphorylates Bad at Ser136 preventing cytochrome c release.  Akt also phosphorylates 
caspase 9 at Ser196, causing a conformational change that results in the inhibition of its 
proteolytic activity (Figure 1.5).  The overall result is protection from apoptosis and 
increased proliferation, events that favor tumorgenesis.
64
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Figure 1.5. Model of PI3K/Akt Pathway Activation.  In response to extracellular stimuli 
(i.e. growth factors), the catalytic subunit of PI3K (p110) is recruited to receptor tyrosine 
kinases (RTKS) at the membrane through its regulator subunit (p85). PI3K phosphorylates 
phosphatidylinositol 4, 5, bisphosphate (PIP2) to generate the second messenger 
phosphatidylinositol 3, 4, 5, trisphosphate (PIP3).  PIP3 recruits serine/threonine Akt and 
3-phosphoinositide dependent kinase (PDK1) to the membrane.  Membrane bound Akt is 
rendered fully active through its phosphorylation by PDK1.  Activated Akt may 
phosphorylate a variety of substrates thereby activating growth and pro-survival proteins or 
inhibiting targets important for cellular growth control and apoptotic responses.
60,64,65
Growth Factors 
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1.9 Receptor Tyrosine Kinases - ERBB receptor family proteins:   
 
This family of proteins consists of four members:  ERBB1 (EGFR), ERBB2 
(Her2), ERBB3 and ERBB4; upon ligand binding, these proteins can homo- or 
heterodimerize and autophosphorylate tyrosine residues found on their cytosolic domains.  
These residues serve as docking sites for SH2 domain proteins that feed into the ERK1/2 
and Akt pathways, molecules that can act as mediators of downstream intracellular 
signaling pathways.
66 
Once activated these molecules lead to the propagation of survival 
signaling as well as the down regulation of pro-apoptotic BH3 domain proteins: BIM, 
BAD and BAK.  ERBB1 receptor over expression is found in over 60% glioblastoma 
multiforme patients.
70
 Deregulation of ERBB receptor signaling in many forms of 
aggressive cancer cells, justifies the current NIH funded studies directed at controlling and 
inhibiting these receptors as therapeutic cancer treatment schemes.  Clinical techniques 
geared towards the inhibition of ERBB receptor activation include: 1) monoclonal 
antibodies (Trastuzumab) that prevent ligand binding and subsequent activation;
67 
2) 
quinazoline-derived small-molecule inhibitors that prevent ATP binding to the kinase 
domains of receptors, preventing downstream signaling protein activation; and 3) siRNA 
knockdown of receptor gene expression.
66,71,72
  Lapatinib has been shown to inhibit ligand 
receptor binding to ERBB1/2 receptors while Sorafenib not only inhibits growth factor 
receptors, but also downstream activated intracellular proteins i.e. Raf family kinases. 
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1.10 Apoptosis: Extrinsic and Intrinsic Pathways 
 
Apoptosis is an energy-dependent process involving the transcription of specific 
proteins leading to a controlled form of cell death.  The induction of apoptosis signaling 
can occur via the activation of either the extrinsic pathway, a receptor-mediated form of 
cell death, or the intrinsic pathway, a mitochondrially-mediated form of cell death.  In 
many cancers, the up-regulation of pro-survival receptor tyrosine kinases and their 
unregulated activation can serve as major mechanisms of promoting drug resistance by 
way of up-regulation of pro-survival BCL-2 family proteins and down regulation of pro-
death BH3-only proteins.
73
   
 Both extrinsic and intrinsic pathways have a common group of cysteine dependent 
aspartate specific proteases called procaspases, which require activation to become full 
caspases and carry out the cleaving of cellular substrates that result in biochemical and 
morphological changes.  Biochemical processes include the externalization of 
phosphatidylserine on the cell surface.  The morphological changes during apoptosis 
include chromatin condensation, cytoplasmic shrinkage, membrane blebbing, and 
phagocytosis of the cell or the cell breaks apart forming apoptotic bodies.
74
   
 The extrinsic pathway involves engagement of death receptors that belong to the 
tumor necrosis factor receptor (TNF-R) family.  Death receptors are activated by their 
natural ligands, TNF family.  Members of the TNF receptor family share similar cysteine–
rich extracellular domains and have a cytoplasmic domain called the “death domain”.  
Death receptors include CD95 (Fas), TRAIL-R1 (APO-2, DR4), TRIAL-R2 (DR5, 
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KILLER, TRICK2), TNF-R1 (CD120a), and DR3 (APO-3, LARD, TRAMP, WSL1).  
Among these receptors, CD95 is the best characterized death receptor.
75
  
Fas is a 45-kDa Type I transmembrane protein, which, like many members of the 
TNF/NGF superfamily, contains a number (three in the case of Fas) of cysteine-rich 
repeats in its extracellular domain. Such cysteine repeats serve as recognition sites for 
respective ligands, disruption of these repeats leads to the loss of ligand binding and 
effector signaling. The Fas receptor is ubiquitously expressed on a variety of normal cells, 
including activated T- and B-cells, hepatocytes, and ovarian epithelial cells, although 
regulated expression has been reported in various systems. High levels of Fas expression 
have also been detected on solid tumors of the breast, ovary, colon, prostate, and liver. In 
contrast, FasL is a Type II cell surface glycoprotein of 40 kDa, which has a cytosolic N-
terminus and an extracellular C-terminus. FasL expression is limited, but has been detected 
on activated T-cells, natural killer cells, Sertoli cells of the testis, and the corneal 
epithelium and the retina of the eye. Some tumors also express FasL, which may be a 
mechanism to escape immune surveillance.  Metalloproteinase-mediated shedding of 
membrane-bound FasL as a soluble form from effector cells, is believed to serve as a 
mechanism of turning off apoptosis in bystander cells.
75
  
Ligation of Fas with FasL (expression of which can be on the same or different 
cells) triggers the combination of Fas monomers into trimeric Fas-complexes.  Trimer 
formation is critical for effector function. The intracellular domain of Fas contains a stretch 
of 80 amino acids known as the death domain (DD). The DD enables the recruitment and 
construction of a multi-protein death-inducing signaling complex (DISC), following Fas 
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trimerization. DISC formation appears to be required for Fas-mediated apoptosis, as it both 
serves as a central relay station to downstream signaling proteins and more importantly, 
provides docking sites for critical effectors in the Fas-death pathway.  Immediately 
following Fas/FasL ligation, there is recruitment of the serine-phosphorylated adapter Fas-
associated DD (FADD)/MORT1.  Fas/FADD interaction is co-ordinated through the 
highly conserved DD motifs found in both proteins.  The presence of a functional FADD is 
critical for Fas-mediated apoptosis, whereby the expression of a dominant-negative FADD 
completely abrogates Fas-induced cell death. Moreover, in vivo studies have revealed a 
substantial attenuation of lymphocyte death in mice lacking FADD. FADD serves as a 
bridge between Fas and downstream molecules, such as Fas-like interleukin (IL)-1β 
converting enzyme (FLICE)/procaspase-8α/β. FADD is a true adapter protein in that it 
harbors an N-terminal DD along with a C-terminal death effector domain (DED). Its 
unique structure enables FADD to proximally bind Fas on one end, while being able to 
distally recruit FLICE on the other.
76
 The caspases that are recruited to the DISC are 
caspase 8 and caspase 10, which are the initiator caspases.  Once these are activated, 
caspase 8 can cleave Bid and the intrinsic pathway is initiated, or caspase 8 can directly 
lead to the activation of executioner caspases (caspase 3, 6, and 7).  The active executioner 
caspases cleave death substrates leading to apoptosis (Figure 1.6).
74
   
 The intrinsic apoptotic pathway involves non-receptor mediated stimuli that 
produce mitochondrial initiated events.  Examples include radiation, hypoxia, free radicals, 
and hyperthermia.  All of these stimuli cause changes in the inner mitochondrial membrane 
that result in mitochondria permeability.
74
 The members of the Bcl-2 family regulate the 
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intrinsic pathway.  Bcl-2 family members are divided into three subfamilies based on their 
function and structure: (1) anti-apoptotic proteins (Bcl-2, Bcl-xL, Bcl-w, Mcl-1, A1/Bfl1, 
Boo/Diva, NR-13) that have four BCL-2 homology domains, (2) pro-apoptotic members of 
the Bax subfamily that have three BH domains (Bax, Bak, Bok/Mtd) and (3) the BH-3 only 
pro-apoptotic proteins (Bik, Bad, Bid, Blk, Hrk, MimL, BNIP3, NOXA, PUMA).   The 
BH-3 domain is present in all members and is essential for heterodimerization among 
members and is the minimum domain required for apoptotic function.
77
   Activation of the 
mitochondrial pore formation and release of cytochrome c is by the Bcl-2 family member, 
Bid.  Bid is cleaved by active caspase 8 and translocates to the mitochondria.  Bid inserts 
into the membrane and activates Bax and Bak leading to mitochondrial membrane 
permeablisation and release of cytochrome c.  Cytochrome c binds the apoptotic protease 
activating factor 1 (Apaf-1) to form the apoptosome.  At the apoptosome, the initiator 
caspase, caspase 9 is activated.  This activation leads to the cleavage and activation of 
executioner caspases converging to the final common pathway leading to cell death 
(Figure 1.6).
78
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Figure 1.6.  The Apoptosis Signaling Pathways.  Apoptosis can be initiated by two 
pathways, the extrinsic pathway through death receptors or the intrinsic pathway through 
the mitochondria.  In both pathways, induction of apoptosis leads to the activation of an 
initiator caspase (caspase 8 or 10 for the extrinsic pathway, and caspase 9 for the intrinsic 
pathway), and activation of executioner caspases, leading to the common pathway of cell 
death. 
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1.11 Regulation of Apoptosis Signaling 
 Death receptor mediated apoptosis can be inhibited by a protein named c-FLIP 
(FADD-like interlukin-1 β-converting enzyme-like protease).  Three splice variants have 
been identified in humans. One termed v-FLIP is found only at the mRNA level, whereas 
the long form (FLIPL) and a short form (FLIPS) are found at the protein level and share 
structural homology with procaspase-8, but lack catalytic activity.  This structural 
homology can allow FLIP to bind to FADD and caspase 8, rendering them ineffective.
76
  
 Anti-apoptotic member, Bcl-2 suppresses cytochrome c release, thereby enhancing 
cell survival.  Bcl-xL interacts with Apaf-1 to prevent the activation of executioner 
caspases and subsequent apoptosis.  Bak is maintained in an inactive state on the surface of 
the mitochondria by binding of Mcl-1 or Bcl-xL until an apoptotic stimulus occurs.  The 
depletion of Mcl-1 in some cells permits Bak oligomerization, activation, and apoptotic 
cell death.
79
       
 Inhibitor of apoptosis (IAP) proteins directly bind and inhibits caspases 3, 7, and 9.  
There are eight mammalian members of the IAP family which include: XIAP, c-IAP1, c-
IAP2, NAIP, ILP-2, survivin and ML-IAP.  There are three proteins that are negative 
regulators of IAP proteins, which include, XIAP-associated factor (XAF1), Second 
mitochondrial activator of caspases/direct IAP binding protein with low pI 
(Smac/DIABLO), and Omi/HtrA2.  These proteins can bind to IAPs and abolish their anti-
apoptotic function.  XAF1 accumulates in the nucleus and can sequester XIAP from the 
cytosol.  Smac/Diablo and Omi/HtrA2 are located in the mitochondria and are released into 
the cytosol upon apoptotic stress.
80
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1.12 Autophagy: Function and Process 
Autophagy is a process of lysosomal protein degradation in which the cell “eats” 
itself.  Autophagy serves as an evolutionary conserved survival mechanism in virtually all 
eukaryotic cells by providing a way for cells to dispose of damaged or aging organelles 
and proteins and allow for the recycling of molecules. However, autophagy can become 
deleterious to cells when upregulated and may play a role in cell death, commonly referred 
to as type II programmed cell death.
81
  Autophagy can be separated into three types, 
macroautophagy, microautophagy, and chaperone-mediated autophagy.  The focus of the 
work in this study will be on macroautophagy (hereafter termed autophagy) because this is 
the most characterized and best understood form of autophagy.
82
   
The first stage of autophagy is vesicle nucleation and begins with a crescent shaped 
double membrane vesicle forming that appears in the cytoplasm.  This membrane 
continues to elongate, entering the elongation stage, while gathering cytoplasmic cargo 
until it closes forming an autophagosome.  The formation of the autophagosome 
constitutes the completion stage.  The docking and fusion stage occurs when the 
autophagosome targets the lysosome and fuses with it allowing the captured material and 
the inner membrane to be degraded (Figure 1.5).  The molecular mechanism(s) of 
autophagy involve genes termed autophagy related genes (ATG) and its products, Atg, first 
found in yeast cells.  The Atg proteins function at distinct stages in the autophagy process, 
most of which have been identified in mammalian cells.
81
  
The assembly of the pre-autophagosome (PAS) is referred to as nucleation (Figure 
1.7).  This step begins with Atg17.  Atg17 recruits Atg13 and Atg9, which together 
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activate the phosphoinositide 3-kinase (PI3K) class III complex to include Atg14, Atg15, 
and vacuolar protein sorting-associated (VPS),
82
 or its mammalian counterpart p150.  
Atg6, Beclin 1 in mammalians, and UV-irradiation resistance-associated tumor suppressor 
gene (UVRAG) also associate with the PI3K complex.  Under conditions of nutrient 
starvation, Atg13 interacts with Atg1 and the PI3K complex to recruit Atg18 and Atg2.  
Atg18 and Atg2 are involved in retrograde transport of Atg9 to the periphery of the cell 
where they aid in membrane recycling.
83
     
Elongation of the autophagosome is generated by two ubiquitin-like conjugation 
systems, Atg12-Atg5 and Atg8-phosphatidylethanolamine (PE).  The class III PI3K 
complex is required for the localization of both systems.  In addition, both systems are 
similar to the ubiquination system, consisting of three enzymes: a ubiquitin-activating 
enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase (E3).
84
 
Atg12 is activated by Atg7 functioning as an E1 enzyme.  Atg10 acts as an E2 enzyme, 
forming a new thioester bond and Atg7 is released.  The last step is the covalent linkage of 
Atg12 to a lysine residue of Atg5 and the release of Atg10.  This Atg12-Atg5 complex 
interacts with Atg16L in mammalians (where Atg16L only binds to Atg5), forming an 800 
kDa structure on the outer membrane necessary for the elongation of the PAS.  Once the 
autophagosome is complete, this conjugate system dissociates and thus is not a part of the 
mature autophagosome.
85
 The second ubiquitination system is Atg8-PE.  Atg8 is a soluble 
cytoplasmic protein that conjugates with PE and becomes attached to the pre-
autophagosome, as well as the mature autophagosome, and the autophagic bodies.
84
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The mammalian ortholog of Atg8, is microtubule-associated protein 1 light chain 3 
(LC3) and this protein is one of two credible markers to detect autophagy in mammalian 
cells. LC3 is detected in two forms, LC3 I (18 kDa) and LC3 II (16 kDa).  LC3 I becomes 
active when it is cleaved by Atg4 also known as autophagin.  Next, with the catalysis of 
Atg7 and Atg3, LC3 I undergo ubiquitination-like reactions and is modified to LC3 II.  
LC3 II is tightly bound to the PAS as well as the autophagosome whereas LC3 I is located 
in the cytoplasm. Thus, the relative amount of LC3 II reflects the abundance of 
autophagosomes present in cells.
84,86
   Another marker, p62, also named sequestosome 1 
(SQSTM1) is a more recent protein that may be used to detect autophagy.  This protein is a 
common component of polyubiquitinated protein aggregates that are degraded by 
autophagy. The C-terminal part of p62 contains an ubiquitin-associated (UBA) domain, 
which binds to ubiquitin non-covalently.  The p62 protein also recognizes LC3 on the 
autophagosome. Positive p62 structures are degraded via autophagy and this protein can be 
recognized along with LC3.
87
 
After the formation of the autophagosome, the fusion with the lysosome follows.  
This structure is commonly referred to as the autolysosome or autophagolysosome.
88
 There 
are several factors involved in autophagosome fusion, these include the SNARE proteins 
(i.e. SEC17, SEC18, and YPT7).  Degradation of the autophagosome once fused requires a 
low pH, proteinase B (PRB1), and the lipase Atg15.  PRB1 is a hydrolase involved in the 
activation of vacuolar zymogens which indirectly affects the vesicle breakdown whereas, 
Atg15 functions directly in vesicle breakdown.
84
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1.13 Autophagy: Regulation 
There are a number of pathways involved in the regulation of autophagy.  A critical 
player in autophagy regulation is the mammalian target of rapamycin kinase (mTOR).  
mTOR is a serine/threonine kinase that is involved in the control of multiple cellular 
processes in response to changes in nutrient conditions.
81
  It exerts an inhibitory signal on 
autophagy, remaining active when the supply of amino acids and other nutrients are ample.  
In an active form, mTOR can phosphorylate proteins that are important for cell growth.   
When a cell is deprived of nutrients, mTOR is inactivated, allowing proteins that are 
required for cell survival to be translated.
86
 Autophagy is therefore the attempt to provide 
an alternate source of nutrients for cell survival. Treatment of cells with rapamycin, an 
inhibitor of mTOR, blocks cell cycle progression and triggers autophagy.  mTOR also 
appears to affect Atg proteins, resulting in interference with autophagosome formation.  
Under nutrient-rich conditions, activated mTOR causes hyperphosphorylation of Atg13, 
thereby preventing the association of Atg13 with Atg1 (Figure 1.7 and 1.8).
88
   
Another signaling pathway involved in the regulation of autophagy are class I 
PI3Ks. Evidence that PI3K was involved in autophagy stems from the use of 3-
methyladenie (3MA), a PI3K inhibitor, that inhibits the autophagic process.  Other PI3K 
inhibitors (i.e. wortmannin and LY294002) have also been shown to inhibit autophagy.
89
 
There are three classes of PI3Ks in mammalian cells. Activation of class I PI3K inhibits 
autophagy in HT29 colon cancer cells.
90
 Class II PI3K does not appear to have an effect on 
autophagy. Class III PI3K plays a significant role in the early steps of autophagy.
83
 In 
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addition, the class III PI3K product, phosphatidylinositol 3-phosphate (PIP3), plays a role 
in the induction of autophagy.
90
 
 
1.14 Autophagy and Cancer 
Autophagy can be activated in response to extra- or intracellular stimuli such as 
starvation, hormone treatment, growth factor deprivation, ER stress and infection. Often 
regarded as a cell survival mechanism, autophagy can play a significant role in cancer cell 
survival and resistance to treatment.  However, other studies have shown that autophagy 
may also have a role in cell death.
82
 
  One of the key proteins involved in the induction of autophagy, beclin 1, displays 
tumor suppressor activity. Beclin 1 is mono allelically deleted in 40-75% of human breast, 
ovarian, and prostate cancers.  Mice with heterogeneous disruption of beclin 1 are more 
prone to developing spontaneous tumors and show a decrease in autophagy.
91
     Beclin 1 
was originally isolated as a Bcl-2 interacting protein.  Furthermore, Bcl-2 downregulation 
stimulates autophagy.  Consequently, beclin 1 mutations that abolish the interaction with 
Bcl-2 or Bcl-xL confer a gain-of-function phenotype with respect to autophagy.  Similarly, 
mutations in Bcl-xL that prevent its binding to beclin 1 also eliminate its capacity to 
antagonize autophagy induction.  The autophagy inducing activity of beclin 1 is also 
inhibited by Mc1-1.
92 
PTEN, a tumor suppressor which dephosphorylates class I PI3K 
products, is shown to prevent autophagy.
91
 Thus, autophagic signaling is tightly linked to 
oncogenic signaling.  Currently, the variability of autophagic signaling in cancer cells is at 
the forefront of discussion in cancer therapy.  
31 
 
 
Figure 1.7.  The Cellular Aspect of Autophagy.  The cellular process of autophagy 
follows distinct stages: vesicle nucleation (formation of the isolation membrane), vesicle 
elongation (growth of the membrane from the preautophagosomal structure to the mature 
autophagosome), docking and fusion of the autophagosome with the lysosome to form an 
autolysosome, and lastly breakdown of the autolysome and the degradation of its contents.  
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Figure 1.8.  The Molecular Aspect of Mammalian Autophagy.  Regulatory steps of 
autophagy, as seen in response to starvation. (Dent et al.) 
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1.15 Molecular Chaperones in Protein Folding 
 
Protein folding is the physical process by which a polypeptide folds into its 
characteristic three-dimensional structure.  Protein structure can be described at four levels.  
The primary structure consists of the amino acid sequence and this determines the three-
dimensional structure.  The secondary structure refers to the polypeptide chain folding into 
a regular structure (i.e. alpha helix, beta sheet, and turns and loops).  The tertiary structure 
is the compact, asymmetric structure in which all proteins have the common features of 
interior amino acids with a hydrophobic side chain and hydrophilic amino acids that can 
interact with the aqueous environment.   The quaternary structure refers to the assembly of 
multi subunit structures.  The correct structure of the protein is essential for its function.  
Thus, incorrect folding usually produces inactive proteins.  The process of folding in vivo 
begins co-translationally so that the protein’s N-terminus begins to fold while the C-
terminus is still being synthesized on the ribosome.
93
          
 Molecular chaperones also known as heat shock proteins (hsps) are ubiquitous in 
nature and act to maintain proper protein folding within the cell or proteasome-mediated 
degradation in the case of damaged proteins.
93
 These proteins facilitate the correct folding 
in vivo but they do not contain steric information regarding the correct folding.  Instead, 
they prevent incorrect interactions within non-native polypeptides increasing the yield but 
not the rate of folding reactions.
93
  The demand upon these heat shock proteins increases 
after environmental stress (i.e. drugs, toxic chemicals, and extreme temperatures), non-
stress conditions, and disease states (i.e. Cancer, Alzheimer’s disease and cystic fibrosis).94   
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 Heat shock proteins are classified by molecular weight into six major hsp families 
to include the small hsps (20-25 kda), and hsp40, hsp60, hsp70, hsp90, and hsp100.
95
 The 
small hsps bind to partially denatured proteins and are responsible for protecting proteins 
from irreversible aggregation via an energy independent process.  Once suitable conditions 
are restored for renewed cellular function, protein release and refolding are mediated by 
ATP-dependent chaperones such as hsp70.
96
 The small hsps also function to maintain the 
integrity of membranes via specific lipid interactions under physiological conditions.
97
 
Hsp40, hsp60, and hsp70 are all involved in nascent protein folding.
93
  Additionally, hsp40 
is considered a co-chaperone for hsp70, playing a vital role in the stimulation of 
conformational changes in the ATPase domain of hsp70.
98
 In addition to stabilization 
processes, Hsp70 is also important in the degradation of misfolded proteins.
93
  The hsp100 
family of chaperones, function to disaggregate proteins and some members of this family 
target specific classes of proteins for degradation.
99
  Hsp90 however, seems to be more 
important in cancer progression, stabilizing a number of signaling proteins involved in 
cancer progression and is it not required for de novo protein synthesis.
100
 (Figure 1.9)  
 
1.16 Hsp90 Structure and Function 
 Hsp90 is a heat shock protein that conserves the folding of newly translated 
protein.
101
 It is distinctly different from other chaperones in that most of its substrates are 
signaling proteins.  Classic examples include steroid hormone receptors and signaling 
kinases.
102,103
  Thus, disruption of Hsp90 in tumor cells has been shown to induce improper 
folding of many proteins, including Raf-1, B-Raf, Akt, and ERBB family receptors 
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culminating in their proteosomal degradation.
104
 Hsp90 is a constitutive homodimer and 
has 3 domains, a 25 kDa N-terminal domain, a charged linker domain, and a 55 kDa C-
terminal domain.  The N-terminal domain binds ATP and other purine analogues,
105
 while 
the C-terminal domain is responsible for dimerization and is required for biologic 
activity.
106,107
  Hsp90 consists of two isoforms, alpha and beta.  Hsp90α is elevated under 
stress conditions whereas hsp90β is constitutively expressed.  The proteins are encoded on 
two separate genes, chromosome 14 for Hsp90α and chromosome 6 for hsp90β.108  
Although there are some functional differences between the two the isoforms,
 109
 they are 
usually not distinguished from each other.
110
  However, a knockout mouse strain for 
hsp90β is embryonic lethal.111   
Hsp90 genes are regulated by a family of transcription factors known as heat shock 
factors (HSFs).  Hsp90 genes contain heat shock-responsive elements in their promoters, 
which are bound by the HSFs to initiate transcription.  There are 4 HSF proteins that 
include HSF1, 2, and 4 which are ubiquitous in nature, and HSF3 which has been 
characterized in avian species.
94
 Of the HSFs, HSF1 is the principal stress-induced 
transcription factor.
112
   
 HSFs consist of four conserved structural domains.  The DNA binding domain is 
characterized by a helix-turn-helix motif.  There is also a hydrophobic repeat domain 
essential for trimer formation and a carboxy-terminal transactivation domain.
114
 Under 
unstressed conditions, HSF1 exists as a cytosolic monomer in complexes containing hsp70 
and hsp90.  Upon exposure to stress, HSF1 is activated and binds to the heat shock 
promoter element (HSE) in hsp promoters.  HSF1 forms a phosphorylated homotrimer in 
36 
the nucleus that activates a program of transcription, including the upregulation of HSP 
production.  
 The transcriptional regulation of HSF1 is controlled in part by heat shock proteins.  
It has been shown that the binding of hsp70 to HSF1 at the hydrophobic carboxy-terminus 
suppresses the function of HSF1.
115
 When there is accumulation of non-native proteins 
during a stressful event, these may compete with HSF1 for binding to chaperone hsp70.  
Unbound HSF1 could then homotrimerize and be available for transcription.
116
 Similarly, 
hsp90 can form a complex with HSF1 and repress its function as well.  Additionally, 
geldanamycin, an inhibitor of hsp90, activates HSF1 in vitro.
117
    
 
 
Figure 1.9 Hsp70 and Hsp90 protein folding and degradation.
81
 
 
 
37 
1.17 Hsp90 inhibitors 
 The highly conserved N-terminal domain of hsp90 is the binding site for 
geldanamycin (GA), an ansamycin drug which specifically targets hsp90,
118
 inhibits the 
hsp90 ATPase with nanomolar affinity.  This drug occupies the nucleotide-binding cleft 
within in the N-terminal domain.
105
 GA acts like a nucleotide that locks hsp90 in an ADP-
bound state, ultimately leading to the inhibition of the two chaperone proteins; p23-hsp90 
interactiing with each other.
120
 Like many chemotherapeutic agents, GA has a dose-
dependent selectivity for tumor cells.  In 
cancer cells, Hsp90 has a higher affinity 
for N-terminal ligands than in normal 
cells.
 119,121
 Thus, GA would 
preferentially target cancer cells rather 
than normal cells since it binds the N-
terminus of hsp90.  Unfortunately, 
studies have shown GA drug toxicity in 
the liver, which has precluded further clinical development.
122
 17-allylamino-17-
demethoxygeldanamycin (17-AAG), a derivative of GA, is a reversible Hsp90 inhibitor, 
and has been shown to have potential anti-tumor activity and is currently undergoing 
clinical phase I trials.  17-AAG seems to undergo extensive metabolism that can result in 
the generation of toxic species 
123
 and ultimately increased levels of ER stress. 
 
 
Figure 1.10 - 17-AAG 
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1.18 ER Stress:  The Unfolded Protein Response 
 
 The endoplasmic reticulum (ER) is a membranous network found throughout the 
cytoplasm of eukaryotic cells.  Serving as the main site of protein biosysnthesis, the ER is 
responsible for the folding, assembly and glycosylation of membrane bound and secretory 
proteins.  Homeostasis within the ER is contingent on the levels of ER stress that can arise 
due to improper folding/processing of proteins.  The pathways, known collectively as the 
unfolded protein response (UPR), are important for normal cellular homeostasis and 
organism development and may play key roles in the pathogenesis of many diseases.
124
   
The UPR is mediated by three ER membrane associated proteins, PERK (PKR-like 
eukaryotic initiation factor 2α kinase), IRE1 (inositol requiring enzyme 1), and ATF6 
(activating transcription factor-6). In a “stress-free” ER, these proteins are inactive due to 
binding by an ER localized HSP70 family chaperone, BiP/GRP78, in their intra-lumenal 
domains, amino-terminal of IRE1 and PERK and carboxy-terminal of ATF6.   When the 
accumulation of misfolded proteins occurs within the ER, BiP/Grp78, dissociates from 
PERK, IRE-1 and ATF6, to assist in protein folding, as a result of depletion of ER 
chaperone reserves.  The dissociation of BiP/GRP78 from PERK enables its dimerization, 
which in turn leads to its autophosphorylation and subsequently, triggers the 
phosphorylation of eukaryotic transcription initiation factor alpha (eIF2α) at serine 51. 124 
Eif2α is required to recruit the initiator methionyl-transfer RNA (Met-tRNAi) to the 40S 
ribosome.  Thus, when eif2α is phosphorylated, it loses its ability to exchange GDP for 
GTP and thus prevents the 40S ribosome and the 60S ribosomal unit from forming the 80S 
initiation complex necessary for translation.  As a result of activated eif2α, inhibition of 
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both translation and cell cycle progression occurs.
125
 In addition, the activating 
transcription factor 4 (ATF4) is translated after eif2α is phosphorylated and is responsible 
for the activation of genes involved in amino acid metabolism, transport, oxidative-
reduction reactions, and ER stress-induced apoptosis.  One of these proteins, C/EBP 
homologous transcription factor (CHOP) is implicated in both growth arrest and cellular 
apoptosis.
124,125
    
In combination with an induction of pro-survival autophagy, this mechanism can 
enable the cell to recover from the accumulation of misfolded proteins.  This UPR has also 
been shown to play a role in the increased production of pro-survival proteins; however, 
under prolonged stress conditions it also has the potential of inducing a toxic form of 
autophagy, and an ATF4-induced expression of CHOP activating caspase 3 and ultimately 
apoptosis.
125,127
 
 Prior to the initiation of apoptosis, a cell will co-ordinate itself with the ER 
associated degradation (ERAD) system, allowing the misfolded proteins to be degraded.  
XBP1 is responsible for increasing the expression of genes encoding proteins required for 
ERAD.  Recent data has shown, that, under prolonged UPR, ER calcium homeostasis is 
significantly disrupted, and caspase 4 is activated.
126 
Caspase 4 activation then leads to the 
cleavage and processing of caspases 9 and 3 into their active cleaved counterparts, 
ultimately leading to apoptosis (Figure 1.11).  
40 
 
 
Figure 1.11 Upon accumulation of misfolded or unfolded proteins in the ER lumen, 
Bip/Grp78 dissociates from UPR sensors PERK, IRE1 and ATF6.  
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1.19 Small Molecule Inhibitors/Drugs used in this study: 
 
 
Figure 1.12 - PD184352 (CI-1040): 
PD184352 (also called CI-1040) is a second 
generation MEK1/2 inhibitor with enhanced 
bioavailability. Acting as an allosteric inhibitor by not 
competing with ATP for its binding site, binding of 
PD184352 outside the ATP and ERK1/2 binding sites on MEK1/2 inhibits the activation of 
MEK1 in cells by greater than 50% at 2nM, a concentration 100 fold lower than that which 
completely inhibits MEK 1 activity in vitro.  This drug is also highly specific for MEK 1/2 
and has shown to reduce levels of DNA synthesis in U87 gliomas.
128
 
 
Figure 1.13 - PI-103: 
Pyridnylfuranopyrimidine Inhibitor, PI-103, is a multi-
kinase inhibitor of PI3K/Akt-mediated signaling.  
Recently, PI-103 has been shown to enhance the efficacy 
of DNA-damaging chemotherapeutic agents, in the 
treatment of GBMs.  This sensitivity is generated by way 
of inhibition of growth and survival cascades as well as the down-regulation of mTOR, 
necessary for the production of protective BCL-2 family proteins.
130
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Figure 1.14 - PX-866: 
A more specific PI3K inhibitor, PX-866 has been 
shown inhibit tumor cell growth in U87 and U251 glioma 
cells.  Much like its counter-part, PI-103, this specific 
inhibitor of PI3K down regulates the product of survival 
proteins, affording the opportunity for a combinatorial 
approach to increase drug efficacy.
130
 
 
 
Figure 1.15 - Rapamycin: 
The mammalian target of rapamycin, mTOR is 
crucial in regulating the proliferation of cancer cells.  
Inhibitors of mTOR, such as rapamycin have been shown 
to have tumor cell killing ability in vivo in U87 glioma 
cells.  Originally synthesized as an antifungal and 
immunosuppressant agent, rapamycin complexes with 
FKBP-12 and binds to and inhibits mTOR, leading to inhibition of IL-2 induced activation 
of p70 S6 kinase.  Unfortunately, if the tumor is re-occurent, the inhibitory attributes of 
rapamycin are greatly diminished.
131
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Figure 1.16 - OSU-03012 (AR-12): 
OSU-03012 is a derivative of Celecoxib, a COX2 
inhibitor.  Although, OSU-03012 does not inhibit COX2, 
it has an order of magnitude greater effect at killing tumor 
cells than Celecoxib.  Recently, our studies have shown 
that OSU-03012 induced cell death in GBM cells, as a 
result of down regulation of BiP/GRP78. This interaction 
prevents Bip from aiding in the proper folding of proteins transported into the ER, 
ultimately leading to an ER stress induced autophagic response, which has a high potential 
for activating apoptotic signaling.
132
 
 
Figure 1.17 - Temozolomide (TMZ): 
An alkylating chemotherapeutic agent that is orally 
administered and can pass the blood brain barrier.  Studies 
have shown TMZ to have cytotoxic effects through the 
methylation of DNA, specifically at the O6 position of 
guanine, resulting in mispairing with thymine during the 
next round of cell cycle DNA replication and ultimately mis-match repair mechanisms 
eliciting an apoptotic response.
6,134
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CHAPTER 2:  MATERIALS AND METHODS  
 
2.1 Materials 
 Phosphate-buffered saline solution (PBS), Dulbecco’s Modified Eagle’s Medium 
(DMEM), RPMI medium, trypsin-EDTA, and penicillin-streptomycin were purchased 
from GIBCOBRL (Invitrogen-GIBCOBRL Life Technologies, Grand Island, NY).  Dr. 
C.D. James, (UCSF) very generously supplied primary human GBM cells (GBM6, 
GBM12, GBM14) and information on the genetic background of such cells. Dr. S. Spiegel 
(VCU) supplied the plasmid to express LC3-GFP. Trypan blue solution, formaldehyde, 6-
Diamidino-2-Phenylidole (DAPI), and dimethyl sulfoxide (DMSO) were all obtained from 
Sigma Chemical (St. Louis, MO).  Anti-GAPDH (37 kDa, 1:1000, mouse monoclonal), 
phospho-PERK (125 kDa, 1:500, rabbit polyclonal), phospho-/total ERK1/2 (42, 44 kDa, 
1:1000, mouse monoclonal), phospho-/total-Akt (60 kDa, 1:1000, rabbit polyclonal), 
phospho-/total-JNK1/2 (46, 54 kDa, 1:1000, rabbit polyclonal), anti-Bcl-xL (30 kDa, 
1:1000, rabbit polyclonal), anti-Mcl-1 (40 kDa, 1:1000, rabbit polyclonal), phospho-/total-
p38  MAPK (38 kDa, 1:1000, rabbit polyclonal), anti-LC3 (17/19 kDa, LC3II/LC3I, 
rabbit polyclonal) antibodies were purchased from both Cell Signaling Technologies 
(Worcester, MA), Santa Cruz Biotechnology (Santa Cruz, CA) and Novus Biologicals 
(Littleton, CO).  All of the secondary antibodies (anti-rabbit-HRP, anti-mouse-HRP, and 
anti-goat-HRP) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).  The 
JNK inhibitor peptide was supplied by Calbiochem (San Diego, CA) as a powder, 
dissolved in sterile dimethyl sulfoxide, and stored frozen under light-protected conditions 
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at −80 °C. MDA-7/IL-24 antibody (35 kDa, Human IL-24 Antibody, 1:500 Rabbit 
Polyclonal) was purchased from GenHunter (Nashville, TN). Other reagents were of the 
highest quality commercially available.
35,36,134 
 
Methods: 
2.2 Generation of Ad.5-mda-7 or Ad. 5/3-mda-7 
 Recombinant serotype 5 and serotype 5/3 adenoviruses to express MDA-7 (Ad.5-
mda-7 and Ad.5/3-mda-7) and control empty vector (Ad.cmv) were generated using 
recombination in HEK293 cells.
18,22,23,135
  
 
2.3 Synthesis of GST-MDA-7 
 A bacterial expression vector containing a 3’-end open reading frame, was fused to 
the glutathione S-transferase (GST) open reading frame in a GST-4T2 vector (Amersham 
Pharmacia) by introducing restriction enzymes BamH1 and Not1 into the mda-7 gene via 
polymerase chain reaction (PCR).  To verify the expression of MDA-7 protein, a culture of 
HEK293 cells were subjected to an overnight inoculation of GST-MDA-7 (1:100 dilution) 
followed by incubation at 25° C until an absorbance of 0.4-0.6 at A600nm was obtained (ref 
12-18-20,24-28,32).  Next, the culture was exposed to 0.1 µM isopropyl-1-thio-β-D-
galactopyranoside for two hours.  The cells were collected by centrifugation and sonicated 
in PBS.  The solution was again centrifuged to obtain soluble protein.  The lysate was then 
bound to a glutathione-agarose column (Amersham Pharmacia) for two hours at 4° C.  The 
column was washed with 50 ml vol/vol of PBS and 10 ml vol/vol of PBS containing 
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500nM sodium chloride.  The bound protein was eluted by passing 20mM reduced 
glutathione through the column, while collecting 1 mL fractions.  The fractions were 
analyzed by gel electrophoresis to determine the presence of bound GST-MDA-7, and 
positive samples were dialyzed in the presence of 1000 µl vol/vol of PBS for four hours, at 
which time the PBS was replaced, and the dialysis repeated for a further four hours.  Final, 
protein concentration was determined by coomassie blue staining, as well as gel 
electrophoresis using an anti-GST-MDA-7 antibody (50 kDa, 1:3000, rabbit polyclonal) 
generated in rabbits by using gel-purified fragments of GST-MDA-7. 
 
2.4 Cell Culture 
GBM6/GBM12/GBM14 glioma cell lines were originally derived from patients at 
the Mayo Clinic (Rochester, MN).  GBM6/GBM12/GBM14 cells were cultured in 
Dulbecco’s modified Eagle’s medium supplemented with 5% (vol/vol) fetal calf serum and 
100 µg/ml (1% vol/vol) penicillin and streptomycin. Cells were incubated in a humidified 
atmosphere of 5% (vol/vol) CO2 at 37 °C. For short-term cell killing assays and 
immunoblotting, cells were plated at a density of 3 × 10
3
/cm
2
 for 36 hours prior to 
treatment with MDA-7/IL-24 and/or various drugs, as indicated.  
Cell Line Media Characteristics 
GBM6 5% DMEM Mutant Variant - ERBB1 vIII 
GBM12 5% DMEM Expresses mutant active full length ERBB1 
GBM14 5% DMEM Mutant PTEN 
GL261 5% DMEM Mouse Glioma Cells 
 
Table 2.1 Cell Line Information. 
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2.5 In vitro Exposure of Cells to GST-MDA-7, Recombinant Adenoviral Vectors and 
all other drugs 
 Cells were treated with various GST-MDA-7 concentrations, as indicated in the 
figure legends.  In Vitro small molecule inhibitor treatments were from a 100 mmol/l stock 
solution of each drug, the maximal concentration of vehicle (dimethyl sulfoxide) in media 
was 0.02% (vol/vol).  Recombinant adenoviruses to express constitutively activated and 
dominant negative (dn) AKT and MEK1 proteins, dn-caspase 9, XIAP, c-FLIP-s, CRM A, 
and BCL-XL were purchased from Vector Biolabs, (Philadelphia, PA). Monolayer cell 
cultures were washed in PBS prior to infection with specific virus in serum-free growth 
medium at a m.o.i. (multiplicity of infection) of 50 (m.o.i. = # of virus particles per cell).    
Cells were incubated for 24 hours to ensure adequate expression of transduced gene 
product prior to drug exposure.  For Ad.mda-7or Ad.cmv infections, cells were infected 12 
hours after plating and a further 12 hours was allowed for expression of the recombinant 
viral transgene before any additional experimental procedure was performed. Cells were 
not cultured in reduced serum media during any study.
23,24 
 
2.6 Assessment of Cell Viability 
  Cells were harvested by trypsinization with trypsin/EDTA for ~10 minutes at 37°C 
Apoptotic/dead cells detached from the culture substratum into the medium were also 
collected. Both fractions were pelleted by centrifugation at 1,500 rpm for 5 minutes. The 
pooled cell pellets were resuspended and mixed with the vital stain trypan blue. 
Incorporation of trypan blue stain into the cell cytoplasm was used as an indicator of cell 
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death. A haemocytometer mounted on a light microscope was used to count a total of 500 
cells from randomly selected fields per experimental point. The percentage of dead cells 
was expressed as a percentage of the total number of cells counted.  For confirmatory 
purposes, the presence of apoptotic cells was evaluated by assessing Hoechst and terminal 
deoxynucleotidyl transferase dUTP nick-end labeling stained cytospin slides for each 
experimental point, under fluorescent light microscopy and determining the number of 
cells exhibiting the “classic” morphological features of apoptosis and necrosis. For each 
condition, 10 randomly selected fields per slide were evaluated, encompassing at least 
1,500 cells. Alternatively, the Annexin V/propidium iodide assay to determine cell 
viability was performed as per the manufacturer’s instructions (BD PharMingen, San 
Diego, CA), using a Becton Dickinson FACScan flow cytometer (Mansfield, MA). 
23,24
 
 
2.7 Colony Formation Assay for Cell Survival 
  Cells were plated from a single cell suspension, (250-500
 
cells/well) in a 6 cm 
dish.  Twenty four hours after plating, cells were treated
 
as specified in the figures, 48 
hours after treatment, the drug-containing media was carefully
 
removed, and fresh media 
lacking
 
drugs was carefully added. The cells were cultured for an
 
additional 10 to 14 days. 
Upon control group colony formation, the medium was removed and the cells washed in 
1X PBS.  The cells were then fixed on to the dish by adding 100% methanol for 10 
minutes.  The methanol was removed and 0.1% (vol/vol) crystal violet stain (Sigma-
Aldrich) was added to the dish for 1 h.  Colonies containing more than 50 cells were then 
counted and normalized to the control cell survival sample. The survival data shown 
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includes individual assays performed at multiple dilutions of cells with a total of three 
dishes per data point, repeated for a total of three experiments.  
 
2.8 Western Blot Analysis for Protein Expression 
 
Cells were plated in 10 cm
3
 dishes for 24 hours prior to treatment.  Twenty four or 
48 h after drug exposure cells were applied to sodium dodecyl sulfate–polyacrylamide gel 
electrophoresis (SDS-PAGE) and immunoblotting. The cells were lysed in either a 
nondenaturing lysis buffer, and prepared for immunoprecipitation or  were washed in PBS 
and then scraped off  the plate by using whole-cell lysis buffer (0.5 M Tris-HCl, pH 6.8, 
2% (w/v) SDS, 10% (v/v) glycerol, 1% (v/v) -mercaptoethanol, 0.02%  (w/v) 
bromophenol blue).  A 1:20 dilution of protease inhibitor cocktail (Roche) and a 1:100 
dilution of phosphatase inhibitor cocktail (Roche) was also added to the lysis buffer.  
When whole cell lysis buffer was used, the samples were vortexed to dislodge the pellet, 
heated at 95-100ºC for 5 minutes and placed immediately on ice. Nondenaturing lysis 
buffer was used, after immunoprecipitation, samples were also boiled in whole-cell lysis 
buffer. 50-100 µg aliquots of boiled samples (depending on the protein analyzed) were 
loaded onto 10–14% SDS-PAGE apparatus and electrophoresed.  Proteins were 
electrophoretically separated and then transferred onto 0.22 µm nitrocellulose for 4 hours 
on ice at 450 mA in transfer buffer (5.8g Tris-base, 2.9g glycine, milli-Q water to 800 ml, 
1.8 ml 20% (w/v) SDS, 200 ml methanol.), and then immunoblotted with appropriate 
primary antibodies against the specific proteins.
23,24
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 The membrane containing transferred proteins was blocked in TBS-tween (TBST) 
buffer containing 5% (w/v) non-fat dry milk for 30 minutes.  Following removal of the 
blocking solution, the desired primary antibody was added at a certain dilution to fresh 
blocking solution.    After overnight exposure to primary antibody at 4ºC with orbital 
shaking, the antibody-blocking solution was removed and the membrane was washed with 
TBST (3 x 15 minutes).  The membrane was then incubated with the corresponding goat 
anti-mouse or rabbit secondary antibody for 2 hours at room temperature with orbital 
shaking.  Following this incubation, the secondary antibody was removed and the 
membrane washed with TBST (3 x 15 minutes).  All immunoblots were visualized using 
an Odyssey Infrared Imager (LI-COR Biosciences, Lincoln, NE) with associated Image 
Studio software. For presentation, immunoblots were opened in PhotoShop CS2 (Adobe 
Systems, Mountain View, CA); the color was removed, and figures were generated in 
PowerPoint (Microsoft Corp., Redmond, WA). 
 
2.9 Plasmid and siRNA Transfections 
 Plasmid DNA (0.5 µg/total plasmid transfected) was diluted into 50 µl of RPMI 
growth media that lacked supplementation with fetal bovine serum or penicillin–
streptomycin and was incubated in solution for 5 minutes at room temperature. 
Lipofectamine 2000 reagent (1 µl) (Invitrogen, Carlsbad, CA) was diluted into 50 µl 
growth media that lacked supplementation with fetal bovine serum or penicillin–
streptomycin and incubated in solution for 5 minutes at room temperature.  The two 
solutions were then mixed together and incubated at room temperature for 30 minutes. The 
51 
total mix was added to each well (4-well glass slide or 12-well plate) containing 200 µl 
growth media that lacked supplementation with fetal bovine serum or penicillin–
streptomycin. The cells were incubated for 4 hours at 37 °C, after which time the media 
was replaced with RPMI growth media containing 5% (vol/vol) fetal bovine serum and 1% 
(vol/vol) penicillin–streptomycin. 
RNA interference or gene silencing for down-regulating the expression
 
of specific 
mRNA was performed using validated
 
target sequences designed by Ambion (Austin, TX). 
Specified siRNA’s were used at 10 nM concentration of the annealed siRNA or the 
negative control, siSCR
 
(a "scrambled" sequence with no significant homology to any
 
known gene sequences from mouse, rat, or human cell lines) were
 
used. The siRNA 
molecules were transfected into cells according
 
to the manufacturer's instructions, similar 
to plasmids above.  
 
2.10 Microscopy for LC3-GFP Expression 
 Where indicated LC3-GFP transfected cells, 12 hours after transfection, were 
infected with either “Ad.cmv” (empty vector) or Ad.mda-7, then cultured for 24 hours prior 
to treatment with specified drug.  Cells were then stained with Lysotracker Red Dye 
(Invitrogen) at the indicated time points for 20 minutes. Lysotracker Red Dye stained cells 
were visualized immediately after staining on a Zeiss Axiovert 200 microscope (Carl 
Zeiss, Wake Forest, NC) using a rhodamine filter. LC3-GFP transfected cells were 
visualized at the indicated time points on the same microscope using the FITC filter. 
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2.11 Intracerebral Inoculation of GBM cells 
Athymic female NCr-nu/nu and C57 BL/6 mice (NCI-Fredrick) weighing ~20 g, 
were used for these studies. Mice were maintained under pathogen-free conditions in 
facilities approved by the American Association for Accreditation of Laboratory Animal 
Care and in accordance with current regulations and standards of the US Department of 
Agriculture, Washington, DC, the US Department of Health and Human Services, 
Washington, DC, and the National Institutes of Health, Bethesda, MD. 
GBM6/GBM12/GBM14 glioma cell lines were originally derived from patients at the 
Mayo Clinic (Rochester, MN).
34
 GBM6/GBM12/GBM14 cells were cultured in 
Dulbecco’s modified Eagle’s medium supplemented with 5% (vol/vol) fetal calf serum and 
100 µg/ml (1% vol/vol) penicillin–streptomycin. Cells were incubated in a humidified 
atmosphere of 5% (vol/vol) CO2 at 37 °C. Mice were anesthetized via intraperitoneal 
administration of (ketamine, 40 mg/kg; xylazine, 3 mg/kg) and immobilized in a 
stereotactic frame (David Kopf Instruments, Tujunga, CA). A 24-gauge needle attached to 
a Hamilton syringe was inserted into the right basal ganglia to a depth of 3.5-mm and then 
withdrawn 0.5-mm to make space for tumor cell accumulation. The entry point at the skull 
was 2-mm lateral and 1-mm dorsal to the bregma. Intracerebral injection of 0.5 × 10
6
 
GBM6/GBM12/GBM14 glioma cells (~40 mice per cell line per separate experiment) in 2 
µl of DMEM (lacking supplementation with fetal bovine serum or with penicillin–
streptomycin) was performed over 10 minutes. The skull opening was enclosed with sterile 
bone wax and the skin incision was closed using sterile surgical staples. Adenoviral 
vectors, Ad.mda-7, Ad.5/3-mda-7, or Ad.cmv were administered 14 days after tumor cell 
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implantation via stereotactic injection into the intracerebral tumor using the same 
anesthesia procedure and stereotactic frame coordinates, as described above. Viral vectors 
(Ad.mda-7, Ad.5/3-mda-7, or Ad.cmv, 1 × 10
8
 plaque-forming units) suspended in 2 µl of 
PBS were delivered by slow infusion over a 6-minute period. For animal studies in chapter 
4, we performed the experiment twice (n = 2) with 5 animals/group. For animal studies in 
chapter 7, we performed the experiment twice (n = 2) and 5 and 6 animals per group.  
 
2.12 Ex Vivo Manipulation of Tumors 
 Animals were euthanized by CO2 and placed in a BSL2 cell culture hood on a 
sterile barrier mat. The bodies of the mice were soaked in 70% (vol/vol) EtOH and the skin 
around skull removed using small scissors, forceps and a disposable scalpel. These 
implements were flame sterilized between removal of the outer and inner layers of skin. A 
piece of the tumor (~50% by volume) was removed and placed in a 10-cm dish containing 
5 ml of RPMI cell culture media, on ice. In parallel, the remainder of the tumor was placed 
in 5 ml of Streck tissue fixative (Fisher Scientific, Middletown, VA) in a 50-ml conical 
tube for fixation.  The tumor sample that had been placed in RPMI was minced with a 
sterile disposable scalpel into the smallest possible pieces then placed in a sterile 
disposable flask. The dish was rinsed with 6.5 ml of RPMI medium, which was then added 
to the flask. A 10× solution of collagenase (Sigma, St Louis MO; 2.5 ml, 28 U/ml final 
concentration), 10× of enzyme mixture containing DNAse (Sigma; 308 U/ml final 
concentration), and pronase (EMD Sciences, San Diego, CA; 22,500 U/ml final 
concentration) in a volume of 1 ml was added to the flask. The flasks were placed into an 
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orbital shaking incubator at 37 °C for 1.5 hours at 150 rpm. Following digestion, the 
solution was passed through a 0.4-µm filter into a 50-ml conical tube. After mixing, a 
sample was removed for viable and total cell counting using a hemacytometer. Cells were 
then centrifuged at 500g for 4 minutes, the supernatant removed, and fresh RPMI media 
containing 10% (vol/vol) fetal calf serum and 1% (vol/vol) penicillin–streptomycin was 
added to give a final resuspended cell concentration of 1 × 10
6
 cells/ml. Cells were diluted 
and plated in 10-cm dishes in triplicate at a concentration of 2–10 × 103 cells/dish. 
 
2.13 Immunohistochemistry and Staining of Fixed Tumor Sections 
 After euthanization, tumors were fixed in Optimum Cutting Temperature (OCT) 
compound (Tissue Tek); cryostat sectioned (Leica, Wetzlar, Germany) as 12-µm sections. 
Nonspecific binding was blocked with a 2% (vol/vol) rat sera, 1% (vol/vol) bovine sera, 
0.1% (vol/vol) Triton X100, 0.05% (vol/vol) Tween-20 solution, then sections were 
stained for cell-signaling pathway markers: MDA-7/IL-24 (rabbit polyclonal IgG, 1:100; 
Gene Hunter, Nashville, TN), anti-Ki67 (mouse IgG, 1:100; Oncogene Science, 
Cambridge, MA), and CD31 (mouse IgG, 1:100; Biomeda, Foster City, CA). For staining 
of sectioned tumors, primary antibodies were applied overnight, sections washed with 
PBS, and secondary antibodies applied for detection (as indicated in the figures): goat anti-
rat Alexa 488/647 (1:500; Invitrogen); goat antimouse Alexa 488/647 (1:500; Invitrogen) 
secondary antibody as per the primary antibody used, or, detected by way of 
Diaminobenzidine (DAB) substrate Peroxidase Detection Kit (Biogenex, San Ramon, CA), 
as per the manufacturer’s instructions. The presence of potentially senescent cells was 
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detected by using a β-galactosidase assay using established procedures. Sections were then 
dehydrated, cleared, and mounted with coverslips using Permount. Apoptotic cells with 
double-stranded DNA breaks were detected using the Upstate TUNEL Apototic Detection 
Kit (Charlottesville, VA) according to the manufacturer’s instructions. Slides were applied 
to high-powered light/confocal microscopes (Zeiss LSM 510 Meta-confocal scanning 
microscope, Zeiss HBO 100 microscope with Axio Cam MRm camera) at the 
magnification in indicated the figures/figure legends. The proliferation zone, which 
included both tumor and normal peritoneal tissue, was usually selected as the site of 
interest, within 2-mm of, or juxtaposed to leading edge of, the tumor.  Data shown are 
representative slides from several sections from the same tumor with multiple tumors 
(from multiple animals and multiple experiments) having been examined (n = at least 3–6 
animals-tumors). 
 
2.14 Data Analysis 
 The effects of various treatments were analysed using one-way analysis of variance 
and a two-tailed Student’s t-test. Results with a P value of <0.05 were considered 
statistically significant. Log-rank statistical analyses between the different treatment 
groups were used for statistical examination of in vivo animal survival data. Experimental 
data shown are the mean values of multiple individual points from multiple experimental 
data sets (+/-SEM). 
 
56 
CHAPTER 3 INTRODUCTION: 
OSU-03012 ENHANCES MDA-7/IL-24 KILLING OF GBM CELLS VIA 
ER STRESS AND AUTOPHAGY AND BY DECREASING 
EXPRESSION OF MITOCHONDRIAL PROTECTIVE PROTEINS 
 
MDA-7/IL-24 cellular toxicity has been shown to be coupled with alterations in 
endoplasmic reticulum stress signaling.
31
 In these studies, MDA-7/IL-24 was shown to 
physically associate with BiP/GRP78 and nullify the protective actions of this ER-
chaperone protein. In addition to virus-administered mda-7/IL-24, delivery of this cytokine 
as a bacterially expressed GST fusion protein, GST-MDA-7, retains cancer-specific 
killing, selective ER localization and is able to induce similar signal transduction changes 
in cancer cells.
31,32
 We have demonstrated that a high concentration of GST-MDA-7 kills 
primary human glioma cells and does so in a PERK-dependent fashion that is dependent 
on elevated levels of autophagy and mitochondrial dysfunction.
34-36
  
The ability of MDA-7/IL-24 to modulate cell-signaling processes in transformed 
cells has been examined by several groups.
22-40
 Prior work by our group indicated that the 
use of bacterially synthesized GST-MDA-7 protein,
32
  in the 0.25– 2.0 nM concentration 
range, primarily produced growth arrest with slight cell killing, whereas at ∼20-fold 
greater concentrations, this cytokine causes profound growth arrest and tumor cell 
death.
32,35,36
 Our group has also demonstrated that Ad.mda-7 kills melanoma cells in part 
by promoting p38 MAPK-dependent activation of growth arrest and DNA damage 
inducible genes, including GADD153, GADD45 and GADD34.
38
 However, in primary 
GBM cells, it was noted that p38 MAPK signaling provided a modest protective signal.
36
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In addition, other groups have argued that inhibition of PI3K signaling, but not ERK1/2 
signaling, modestly promotes Ad.mda-7 lethality in breast and lung cancer cells.
39,40
  
The present studies were designed to evaluate the relative merit of enhancing 
autophagy in parallel with expression of MDA-7/ IL-24, using the novel drug OSU- 03012 
(AR-12).
136,137
  Presently entering Phase I trials, OSU-03012, unlike its parent drug 
celacoxib, does not inhibit COX2 but has an order of magnitude greater toxicity towards 
tumor cells. Our prior studies have demonstrated that OSU-03012, like MDA-7/IL-24, is 
able to kill primary human GBM cells in a PERK-dependent fashion.
137
 However, unlike 
MDA-7/IL-24, OSU-03012 lethality was dependent on AIF release from the 
mitochondrion and not on cytochrome c and caspases.
136
 The present study indicates that 
Ad.mda-7 induced cell killing is enhanced by OSU-03012, and that the cell death does not 
correlate with enhanced additional PERK phosphorylation. The induction of cell killing is 
nonetheless dependent on increased levels of toxic autophagy and mitochondrial dysfunc-
tion.
138,139
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CHAPTER 4 RESULTS: 
OSU-03012 ENHANCES MDA-7/IL-24 KILLING OF GBM CELLS VIA 
ER STRESS AND AUTOPHAGY AND BY DECREASING 
EXPRESSION OF MITOCHONDRIAL PROTECTIVE PROTEINS 
 
4.1 Ad.mda-7 lethality in GBM’s is enhanced by OSU-03012  
 Primary human GBM cells (GBM6, 12 and 14) were plated in 12-well plates (~2.5 
x 10
4
 cells per well) for 24h, infected with 10 m.o.i. empty vector control virus (Ad.cmv) 
or virus to express MDA-7/IL-24 (Ad.mda-7), Twelve hours after infection, cells were 
treated with vehicle (DMSO) or OSU-03012 (1 μM). Forty-eight hours after infection, 
cells were isolated and cell viability was determined by trypan blue exclusion assay 
(±SEM, n = 3).  Results indicated that treatment of Ad.mda-7 infected GBM cells with 
OSU-03012 led to a greater than additive enhancement in tumor cell killing in comparison 
to the individual agents alone (Figure 4.1). 
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Figure 4.1 - Ad.mda-7 lethality is enhanced by OSU-03012. GBM6, GBM12 and 
GBM14 cells were infected with empty vector control virus (Ad.cmv) or with virus to 
express MDA-7/IL-24 (Ad.mda-7) and 12 h after infection treated with vehicle (DMSO) or 
OSU-03012 (OSU, 1 μM). Forty-eight hours after infection cells were isolated and cell 
viability was determined by trypan blue exclusion assay (±SEM, n = 3).  
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4.2 Ad.mda-7 and OSU-03012 synergize to kill GBM 6 cells in colony formation 
assays 
A single cell suspension of GBM6 cells was plated (~250 cells/well) in sextuplicate 
and infected with Ad.cmv or Ad.mda-7, 24 h after plating. Cells were treated with vehicle 
(DMSO) or OSU-03012 (1 μM), 12 h after infection. Forty-eight hours after infection the 
growth media was removed and replaced with fresh media lacking drugs. Colonies of >50 
cells were permitted to form over the following 10-14 days.  After 10-14 days cells 
forming the colonies were fixed, stained and counted (±SEM, n = 3).  Results from this 
study, in close agreement with the cell death assays, suggested that OSU-03012 
significantly (* p < 0.05) enhanced Ad.mda-7 lethality in GBM6 cells, as indicated by a, 
dramatic reduction in cell survival.  
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Figure 4.2 Ad.mda-7 lethality is enhanced by OSU-03012.GBM6 cells were plated as 
single cells in sextuplicate and 12 h after plating infected with Ad.cmv or Ad.mda-7 and 12 
h after infection treated with vehicle (DMSO) or OSU-03012 (OSU, 1 μM). Forty-eight 
hours after infection the growth media was removed and replaced with new media lacking 
drugs. Colonies of >50 cells were permitted to form over the following ∼20 d, followed by 
fixing, staining and counting (±SEM, n = 3). 
 
 
 
 
 
 
 
 
 
 
 
 
* 
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4.3 Ad.mda-7 infected GBM 6 cells treated with OSU-03012 revealed decreased levels 
of pro-survival proteins: BCL-XL, MCL-1 and a reduction in the phosphorylation of 
ERK1/2 
To further elucidate the mechanistic actions of Ad.mda-7/OSU-03012 
combinational killing of GBM tumor cells, GBM6 cells were plated in 6 cm
2
 dishes 
(~2x10
6
 cells/dish) and infected for 24 h with Ad.cmv or Ad.mda-7  prior to treatment with 
vehicle (DMSO) or OSU-03012 (1 μM). Twenty-four and 48 h after infection, cells were 
isolated and SDS PAGE performed on cell lysates to determine the expression of BCL-XL 
and MCL-1, as well as the phosphorylation state of ERK1/2, p38 MAPK, JNK1-3, AKT 
(S473) (n = 2).  The results suggested that treatment of Ad.mda-7 infected cells with OSU-
03012 facilitated a MDA-7/IL-24-induced reduction in the expression of the anti-apoptotic 
proteins BCL-XL and MCL-1 and decreased activity of the pro-survival protein, ERK1/2 
(Figure 4.3).  
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Figure 4.3 Ad.mda-7 inhibition of pro-survival proteins is enhanced by OSU-03012. 
GBM6 cells were infected with Ad.cmv or Ad.mda-7 and 12 h after infection treated with 
vehicle (DMSO) or OSU-03012 (OSU, 1 μM). Twenty-four hours and 48 h after infection 
cells were isolated and SDSPAGEperformed to determine the expression of BCL-XL and 
MCL-1, and the phosphorylation of ERK1/2, p38 MAPK, JNK1-3, AKT (S473) (n = 2). 
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4.4 Overexpression of BCL-XL, or inhibition of components of the intrinsic apoptosis 
pathway in GBM 6 cells were shown to reduce Ad.mda-7 or OSU-03012 toxicity as 
single agents or in combination 
 Treatment of Ad.mda-7 infected GBM6 with OSU-03012 was shown to 
profoundly affect the expression of multiple anti-apoptotic proteins, ultimately enabling 
the induction of apoptosis. The respective role(s) of the intrinsic and/or extrinsic pathways 
of apoptosis in cell death was assessed.  GBM6 cells were plated in 12-well plates (~2.5 x 
10
4
 cells per well) for 24h. Cells were then infected with (all virus infections at 10 m.o.i.) 
empty vector control virus (Ad.cmv) or virus to express MDA-7/IL-24 (Ad.mda-7). Twelve 
hours after infection cells were again infected with viruses to either express XIAP, BCL-
XL, and dominant negative caspase 9 or c-FLIP-s. Twelve hours after infection, cells were 
treated with vehicle (DMSO), or OSU-03012 (1 μM). Forty-eight hours after initial 
infection with mda-7 or apototic regulatory proteins, cells were isolated and cell viability 
was determined by trypan blue exclusion assay (±SEM, n = 3). These results suggested 
that overexpression of the anti-apoptotic protein BCL-XL, or inhibition of components 
involved in the intrinsic apoptosis pathway, reduced Ad.mda-7 or OSU-03012 toxicity 
when used as single agents, and abolished the enhanced cell killing seen as a result of the 
interaction between these agents. Inhibition of the extrinsic pathway, as judged by the 
overexpression of the caspase 8 inhibitor c-FLIP-s, did not alter Ad.mda-7 or OSU- 03012 
lethality (Figure 4.4). 
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Figure 4.4 Overexpression of BCL-XL or inhibition of components of the intrinsic 
apoptotic pathway reduced Ad.mda-7 or OSU-03012 toxicity. GBM6 cells were 
infected with Ad.cmv or Ad.mda-7 in combination with viruses to express XIAP, BCL-XL, 
dominant negative caspase 9 or c-FLIP-s, and 12 h after infection treated with vehicle 
(DMSO), or OSU-03012 (OSU, 1 μM). Forty-eight hours after infection cells were isolated 
and cell viability was determined by trypan blue exclusion assay (±SEM, n = 3). 
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4.5 Activation of MEK protects GBM 6 cells from MDA-7/IL-24 and OSU-03012 
toxicity 
 Since our data indicated that ERK1/2 was significantly inactivated in cells treated 
with OSU-03012 + Ad.mda-7, an assessment of whether maintenance of ERK1/2 activity 
was able to modulate OSU-03012 + Ad.mda-7 mediated toxicity was performed.  GBM6 
cells were plated and infected with (all virus infections at 10 m.o.i.) empty vector control 
virus (Ad.cmv) or with viruses to either express MDA-7/IL-24 (Ad.mda-7) or a 
constitutively active form of MEK1 (MEK1 EE).   Twelve hours after infection, cells were 
treated with vehicle (DMSO) or OSU-03012 (1 µM). Cells were isolated 48 h after 
infection and cell viability was determined by trypan blue exclusion assay (±SEM, n=3). 
Results from this study indicated that the expression of constitutively activated MEK1 EE 
was sufficient to maintain ERK1/2 phosphorylation, acting to also partially sustain 
expression of the anti-apoptotic proteins BCL-XL and MCL-1 in the presence of Ad.mda-
7+OSU-03012 combination treatment (Figure 4.5). 
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Figure 4.5 Activation of MEK and constitutive MCL-1 expression protect GBM cells 
from MDA-7/IL-24 and OSU-03012 toxicity. GBM6 cells were infected with empty 
vector control virus (Ad.cmv) or with viruses to express MDA-7/IL-24 (Ad.mda-7) or a 
constitutively active form of MEK1 (MEK1 EE). Twelve hours after infection cells were 
treated with vehicle (DMSO) or OSU-03012 (OSU, 1 μM). Cells were isolated 48 h after 
infection and cell viability was determined by trypan blue exclusion assay (±SEM, n = 3). 
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4.6 Constitutive expression of MCL-1 protects GBM 6 cells from MDA- 7/IL-24 and 
OSU-03012 toxicity 
Dramatic changes in the cytoprotective protein levels of Mcl-1 and not Bcl-xL were 
noticed. In this study, a role for OSU-03012 in enhancing Ad.mda7 cell lethality by 
facilitating MDA-7/IL24 induced down regulation of specific mitochondrial protective 
proteins was assessed. GBM6 cells were infected with empty vector control virus (Ad.cmv) 
or with a virus to express MDA-7/IL-24 (Ad.mda-7) and, in parallel, transfected with 
either a control plasmid or a plasmid to express MCL-1. Twelve hours after 
infection/transfection, cells were treated with vehicle (DMSO) or OSU-03012 (OSU, 1 
μM). Cells were isolated 48 h after infection and cell viability was determined by trypan 
blue exclusion assay (±SEM, n = 3).  The results indicate that overexpression of 
cytoprotective MCL-1 protected GBM cells from OSU-03012 + Ad.mda-7 induced 
lethality (Figure 4.6). 
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Figure 4.6 Constitutive MCL-1 expression protects GBM cells from MDA-7/IL-24 
and OSU-03012 toxicity. GBM6 cells were infected with empty vector control virus 
(Ad.cmv) or with viruses to express MDA-7/IL-24 (Ad.mda-7) and in parallel transfected 
with a control plasmid or a plasmid to express MCL-1. Twelve hours after infection cells 
were treated with vehicle (DMSO) or OSU-03012 (OSU, 1 μM). Cells were isolated 48 h 
after infection and cell viability was determined by trypan blue exclusion assay (±SEM, n 
= 3). 
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4.7 OSU-03012 treatment enhances Ad.mda-7 induced toxic autophagy but does not 
promote additional activation of PERK in primary human GBM cells  
In this study, GBM6 cells were infected with Ad.cmv or Ad.mda-7, and 
subsequently 12 h after infection, the cells were treated with either vehicle (DMSO) or 
OSU-03012 (1 μM). Cells were isolated 24 and 48 h after infection and SDSPAGE and 
immunoblotting was performed to determine the presence of  phosphorylated PERK and 
the conversion of LC3 to LC3-II (n = 3). Infection of primary human GBM cells with 
Ad.mda-7 was shown to activate PERK however; treatment of GBM 6 cells expressing 
MDA-7/IL-24 with OSU-03012 did not cause additional PERK activation, instead leading 
to a reduction in PERK phosphorylation. OSU-03012 + Ad.mda-7 treatment was shown to 
increase the processing/expression of LC3-II to a greater extent than that induced by 
treatment of cells with the individual agents. These results indicate that the therapeutic 
combination of OSU-03012 + Ad.mda-7 is able to induce elevated levels of autophagy 
(Figure 4.7). 
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Figure 4.7 OSU-03012 treatment enhances Ad.mda-7-induced toxic autophagy but 
does not promote additional activation of PERK. GBM6 cells were infected with 
Ad.cmv or Ad.mda-7 and 12 h after infection treated with vehicle (DMSO) or OSU-03012 
(OSU, 1 μM). Cells were isolated 24 and 48 h after infection, SDSPAGEand 
immunoblotting was performed to assess the phosphorylation of PERK and the conversion 
of LC3 to LC3-II (n = 3). 
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4.8 Expression of dominant negative PERK suppresses the lethal interaction between 
OSU-03012 and Ad.mda-7 in primary human GBM cells 
 This study further assessed the role of PERK in the toxicity induced by OSU-03012 
+ Ad.mda-7 treatment. GBM6 cells were infected with Ad.cmv or Ad.mda-7 and in parallel 
transfected with either an empty vector plasmid (CMV) or a plasmid to express dominant 
negative PERK (dnPERK). Twelve hours after infection cells were treated with vehicle 
(DMSO) or OSU-03012. Forty-eight hours after infection the cells were isolated and cell 
viability was determined by trypan blue dye exclusion assay (±SEM, n = 3).  Although 
OSU-03012 + Ad.mda-7 treatment does not further increase the expression of PERK, 
compared to single agent treatments, these results indicated that the expression of dnPERK 
was still able to suppress the lethal interactions between OSU-03012 and Ad.mda-7/IL-24 
(Figure 4.8). 
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Figure 4.8 Expression of dominant negative PERK suppresses the lethal interaction 
between OSU-03012 and Ad.mda-7 in primary human GBM cells. GBM6 cells in were 
infected with Ad.cmv or Ad.mda-7 and in parallel transfected with either an empty vector 
plasmid (CMV) or a plasmid to express dominant negative PERK (dnPERK). Twelve 
hours after infection cells were treated with vehicle (DMSO) or OSU-03012. Forty-eight 
hours after infection cells were isolated and cell viability was determined by trypan blue 
dye exclusion assay (±SEM, n = 3). 
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4.9 The additive increase of LC3-GFP vesicularization in GBM cells caused by OSU-
03012 and Ad.mda-7 is blocked by expression of dominant negative PERK 
The role of OSU-03012 + Ad.mda-7 in cell death mediated by toxic autophagy was 
assessed. GBM6 cells were plated (2.5x10
4
 cells/well) in four-well chamber slides and 
infected with Ad.cmv or Ad.mda-7 and concurrently, cells were transfected with a plasmid 
to express LC3-GFP and with either an empty vector plasmid (CMV) or a plasmid to 
express dominant negative PERK (dnPERK). In parallel, cells were transfected with either 
scrambled siRNA (siSCR) or a siRNA to specifically knock down autophagy inducing 
protein, Beclin1 (siBeclin1).  Twelve hours after infection cells are treated with vehicle 
(DMSO) or OSU-03012 and twelve hours after drug treatment cells were examined using a 
fluorescent microscope (40x magnification) for the formation of intense GFP positive 
stained vesicles (±SEM, n = 3).  The results indicated that GBM6 cells treated with OSU-
03012 + Ad.mda-7 display an additive increase in the vesicularization of a transfected 
LC3-GFP construct, suggesting that autophagy occurred. Further confirmation of these 
findings was provided through the indication that the toxic autophagic effect was blocked 
by expression of dominant negative PERK or by knock down of Beclin 1 (Figure 4.9). 
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Figure 4.9 The additive increase of LC3-GFP vesicularization in GBM cells caused by 
OSU-03012 and Ad.mda-7 is blocked by expression of dominant negative PERK. 
GBM6 cells in four-well chambered slides were infected with Ad.cmv or Ad.mda-7 and in 
parallel transfected with a plasmid to express LC3-GFPand with either an empty vector 
plasmid (CMV) or a plasmid to express dominant negative PERK (dnPERK). Twelve 
hours after infection cells are treated with vehicle (DMSO) or OSU-03012. Twelve hours 
after drug treatment cells were examined using a fluorescent microscope (40x 
magnification) for the formation of intense GFPstaining vesicles (±SEM, n = 3). 
 
76 
4.10 Knockdown of ATG5 or Beclin1 expression reduced the toxicity of Ad.mda-7, 
OSU-03012 or the combination in GBM cells  
To further assess the role of autophagy induced by OSU-03012 + Ad.mda-7 
treatment, GBM6 cells were simultaneously infected with Ad.cmv or Ad.mda-7 and 
transfected with either siSCR or siRNAs to knockdown autophagy inducing proteins 
Beclin1 (siBeclin1) or ATG5 (siATG5). Twelve hours after infection/transfection, cells are 
treated with vehicle (DMSO) or OSU-03012 (1 μM).  Forty-eight hours after drug 
treatment the cells were isolated and cell viability was determined by trypan blue exclusion 
assay (±SEM, n = 3).  These results indicated that knockdown of ATG5 or Beclin1 
expression resulted in a profound reduction in the cellular toxicity of Ad.mda-7, OSU-
03012 and combined treatment with both agents in GBM6 cells (Figure 4.10). 
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Figure 4.10 Knockdown of ATG5 or Beclin1 expression reduced the toxicity of 
Ad.mda-7, OSU-03012 or the combination in GBM cells.  GBM6 cells were infected 
with Ad.cmv or Ad.mda-7 and in parallel transfected with either a scrambled siRNA 
(siSCR) or siRNAs to knockdown Beclin1 (siBeclin1) or ATG5 (siATG5). Twelve hours 
after infection cells are treated with vehicle (DMSO) or OSU-03012 (OSU, 1 μM). Forty-
eight hours after drug treatment cells were isolated and cell viability was determined by 
trypan blue exclusion assay (±SEM, n = 3). 
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4.11 MDA-7/IL-24 enhances the toxicity of ionizing radiation  
 In addition to a role in inducing cytotoxic autophagy and sensitization to OSU-
03012, studies next investigated the effect of MDA-7/IL-24 upon radiation sensitivity and 
the presence of a “by-stander” cell killing capacity.  GBM6 cells were infected with 
Ad.cmv or Ad.mda-7.  Forty-eight hours after infection cells and media were collected 
separately.  The conditioned media was placed onto uninfected GBM6 cells, and 24 h after 
media addition these cells were irradiated (4 Gy). Forty-eight hours after addition of the 
conditioned media (as described in the Methods section) to the cells, cell viability was 
determined by trypan blue dye exclusion assay (±SEM, n = 3).  These results indicate that 
the conditioned media from Ad.mda-7 infected GBM cells played a role in enhancing the 
toxicity of ionizing radiation in uninfected GBM cells (Figure 4.11).  To further establish 
the effect of Ad.mda-7 on uninfected cells, conditioned media was applied and along with 
ionizing radiation. 
 
 
 
 
 
 
 
 
 
79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 MDA-7/IL-24 sensitizes GBM6 cells to radiation. GBM6 cells were 
infected with Ad.cmv or Ad.mda-7. Forty-eight hours after infection cells and media were 
isolated. Cell viability was determined by trypan blue dye exclusion assay (±SEM, n = 3). 
The media was placed onto GBM6 cells and 24 h after media addition cells were irradiated 
(4 Gy). Forty-eight hours after placement of conditioned media onto the cells, cell viability 
was again determined by trypan blue dye exclusion assay (±SEM, n = 3). 
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4.12 Transfection of uninfected GBM cells with siRNA to knock down MDA-7/IL-24 
expression prevented conditioned media from Ad.mda-7 infected GBM cells from 
increasing MDA-7/IL-24 expression, as well as enhancing the toxicity of OSU-03012 
or ionizing radiation 
GBM6 cells were infected with Ad.cmv or Ad.mda-7 and forty-eight hours after 
infection, the cells and media were isolated and cell viability was determined by trypan 
blue dye exclusion assay (±SEM, n = 3). The media was added to uninfected GBM6 cells 
that had previously been transfected with plasmids to either express a control shRNA 
(shSCR) or a shRNA to knock down MDA-7/IL-24 expression (shMDA-7).  Thirty 
minutes after media addition cells were exposed to radiation (4 Gy) and treated with 
vehicle (DMSO) or OSU-03012 (1 μM). Forty-eight hours after the addition of conditioned 
media to the cells, cell viability was again determined by trypan blue exclusion assay 
(±SEM, n = 3).  All results imply that the conditioned media from Ad.mda-7 infected 
GBM cells was able to induce expression of MDA-7/IL-24 in uninfected GBM cells. 
Furthermore, these cells displayed enhanced toxicity to ionizing radiation compared to 
control treated cells (Figure 4.12).  Transfection of uninfected GBM cells with a siRNA to 
knock down MDA-7/IL-24 expression was shown to prevent the effects of conditioned 
media from Ad.mda-7 infected GBM cells increasing MDA-7/IL-24 expression. In 
addition, the enhanced toxicity to OSU-03012 and ionizing radiation was also significantly 
reduced in these cells.  
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Figure 4.12 MDA-7/IL-24 stimulates expression of MDA-7/IL-24 and increases 
toxcicity of GBM6 cells to drug and ionizing radiation. GBM6 cells were infected with 
Ad.cmv or Ad.mda-7. Forty-eight hours after infection cells and media were isolated. Cell 
viability was determined by trypan blue dye exclusion assay (±SEM, n = 3). The media 
was placed onto GBM6 cells that had been transfected with plasmids to express a control 
shRNA (shSCR) or an shRNA to knock down MDA-7/IL-24 expression (shMDA-7) 
(labeled in parentheses, grey). Thirty minutes after media addition cells were treated with: 
(a) radiation (4 Gy) or; (b) vehicle (DMSO) or OSU-03012 (OSU, 1 μM). Forty-eight 
hours after placement of conditioned media onto the cells, cell viability was again 
determined by trypan blue exclusion assay (±SEM, n = 3). Inset Panel: conditioned media 
containing MDA-7/IL-24 induces MDA-7/IL-24 in uninfected GBM cells that is blocked 
by shRNA knockdown of MDA-7/IL-24. 
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CHAPTER 5 DISCUSSION:  
OSU-03012 ENHANCES MDA-7/IL-24 KILLING OF GBM CELLS VIA 
ER STRESS AND AUTOPHAGY AND BY DECREASING 
EXPRESSION OF MITOCHONDRIAL PROTECTIVE PROTEINS 
 
Previous studies, in both our laboratory and others, have shown that GST-MDA-
7/IL-24 or Ad.mda-7/IL-24 is able to reduce cellular proliferation and cause tumor cell-
specific killing of malignant glioma cells via the induction of a toxic form of 
autophagy.
35,36,141,142,145
 We have also shown that OSU-03012 also kills GBM cells through 
the induction of autophagy thus the data presented in Chapter 4 was designed to establish 
whether OSU-03012 and Ad.mda-7/IL-24 display a cooperative action in GBM cell killing, 
and determine the  mechanisms involved in their mutual action.  
Infection of GBM cells with a 10 m.o.i dose of Ad.mda-7/IL-24 was shown to 
cause modest levels of toxicity at ∼48 h post drug exposure. These results closely 
correlated with the activation of the pro-apoptotic JNK1/2 and p38 MAPK pathways, as 
well as the phosphorylation of ER-stress related protein, PERK.  In addition, the 
combination of OSU-03012 and Ad.mda-7/IL-24 was shown to suppressed the pro-
growth/survival ERK1/2 and, to a lesser extent, AKT signaling cascades.  Multiple studies 
using a number of toxic stimuli have documented that prolonged JNK1-3 and/or p38 
MAPK activation in a wide variety of cell types, can lead to cell death.
134,140-145
 It is well 
established that the balance between the ERK1/2 and JNK1-3 signaling plays a key role in 
homeostatic balance that distinguishes between cell survival versus cell death processes.
140-
145
 Prior studies in primary human GBM cells using GST-MDA-7/IL-24, have 
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demonstrated that inhibition of the ERK1/2 signaling cascade represents a key pro-
apoptotic effect generated by GST-MDA-7 exposure.  Also, treating GBM cells with OSU-
03012 as a single agent at low concentrations does not significantly modulate the activity 
of any of the widely examined signal transduction pathways, e.g., ERK1/2, JNK1/2, p38 
MAPK or AKT.
141-142
 In the work presented here, OSU-03012 was able to further enhance 
the MDA-7/IL-24-induced suppression of ERK1/2 signaling, which in turn was shown to 
result in a significantly reduced expression of the mitochondrial protective proteins MCL-1 
and BCL-XL.  
Infection of GBM cells with Ad.mda-7/IL-24 was shown to decrease the expression 
of BCL-XL and MCL-1, an affect which has previously been demonstrated with GST-
MDA-7. The latter case has been attributed to ER stress signaling via activation of PERK-
eIF2α.35,36,145 Reduced MCL-1 and BCL-XL expression was able to facilitate 
mitochondrial dysfunction and the release of cytochrome c into the cytosol. In addition, we 
have recently published work indicating that the reduced expression of these anti-apoptotic 
proteins was shown to enhance the induction of autophagy by increasing the levels of free 
Beclin1.
41,145,146
 Unbound Beclin1 has been shown to interact with Vps34 to promote 
autophagy.
146
 We have also demonstrated that MDA-7/IL-24 mediated induction of 
JNK1/2 pathway signaling was able to mediate the activation of the pro-apoptotic proteins 
BAX and BAK. OSU-03012 was unable to further increase JNK1/2 signaling levels. Thus, 
the possibility exists that MDA-7/IL-24 is able to induce an increased expression of pro- 
apoptotic proteins and a concomitant reduction in anti-apoptotic proteins, potentially 
inhibiting protective signaling pathways, leading to greater levels of tumor cell death. 
84 
Prior studies have demonstrated that as single agents, the lethality of both GST-
MDA-7/IL-24 and OSU-03012 seen in GBM cells, required the induction of a toxic form 
of autophagy and that this process  was dependent upon PERK signaling.
35,36
 A less than 
additive lethal interaction when Ad.mda-7/IL-24 and OSU-03012 are used in combination 
to kill GBM cells would argue that both of these agents were acting upon a single 
molecule, e.g., PERK, in the promotion of toxic autophagy and cell death.  Alternatively, if 
Ad.mda-7/IL-24 and OSU-03012, when used in combination to kill GBM cells, induced a 
greater than additive amount of cell killing, both agents would be expected to have 
individual modes of action/targets.  Although OSU-03012 did not further enhance MDA-7/ 
IL-24-induced PERK activation or JNK1/2 signaling, when used in combination Ad.mda-
7/IL-24 and OSU-03012 were shown to induce an additive increase in LC3-II levels and in 
the vesicularization of a transfected LC3-GFP construct. The inhibition of autophagy, 
either at the level of PERK inhibition or by the knock down of ATG5/Beclin1, was shown 
to block the lethal interaction between Ad.mda-7/IL-24 and OSU-03012. 
BiP/GRP78 has been defined as a key target for MDA-7/IL-24. The binding of 
MDA-7/IL-24 to this chaperone protein, results in the release and subsequent activation of 
PERK.
31
 Several initial reports argue that the lethality of OSU-03012 in tumor cells may 
be due to inhibition of the enzyme PDK-1, part of the PI3 kinase pathway, and OSU-
03012, millimolar range, has been shown to suppress AKT phosphorylation and 
measurable inhibition of PDK-1 activity.
136,137
 In addition, OSU-03012 interacts with 
multiple kinase inhibitors to kill tumor cells in a manner that appears to be caspase 
independent. OSU-03012 has also been shown to enhance HSP70 and decrease HSP90 
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expression. As a result, the key mode of action for this drug may be to alter chaperone 
protein function, this in turn may have an effect upon the correct processing/folding of 
many different proteins, including those with the ability to stabilize lysosomes and 
mitochondria. Indeed,
132
 recent studies have demonstrated that OSU-03012 treatment was 
able to suppress expression of BiP/GRP78 and did so through reduced stability of the 
protein. In this work, knock down of BiP/GRP78 was shown to enhance OSU lethality and 
overexpression of BiP/GRP78 was shown to abolish OSU toxicity. Further detailed studies 
will be required to fully unravel the biological consequences and molecular basis of the 
actions of OSU-03012 upon cancer cells.  
GBM was one of the first malignancies considered to be treatable through viral 
delivery of genetic-based therapeutics.
41
 However, a problem of efficacy, exists for all 
gene therapy approaches, a problem that is intensified by the highly invasive and diffuse 
nature of GBM’s as compared to other tumor cell types.  This problem signifies the need 
for the development of a toxic ‘bystander’ effect in tumor cells that have not been infected 
by the virus during the primary infection process.  By the rules of simple mass-action, i.e., 
with the total number of non-transformed cells within and around a GBM tumor, compared 
to the total number of transformed cells in a tumor and the total number of virus particles 
infused. Thus, it is not possible for all tumor cells in a highly invasive tumor cell type such 
as GBM to be infected by a non-replicative virus.  Furthermore, many prior studies with 
GBM involving the use of gene therapeutic vectors, have often expressed intracellular 
proteins that are not normally expressed or secreted, which will frequently result in only 
the cells that have been virally infected being subjected to the actions of the therapeutic 
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agent.  The expression of MDA-7/IL-24 overcomes this limitation associated with lack of a 
‘bystander’ effect following gene therapeutic intervention seen in the majority of previous 
studies.
138,139
  We have found that, as a cytokine, MDA-7/IL-24 is secreted from infected 
GBM cells into the surrounding media and this MDA-7/IL-24 conditioned media has been 
shown to induce apoptosis in uninfected GBM cells and to promote the toxic effects seen 
with either OSU-03012 or ionizing radiation.  
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CHAPTER 6 INTRODUCTION:  
INHIBITORS OF MULTIPLE PROTECTIVE SIGNALING 
PATHWAYS AND Ad.5/3 DELIVERY ENHANCES MDA-7/IL-24 
KILLING 
 
The ability of MDA-7/IL-24 to modulate cell-signaling processes in transformed 
cells has been investigated by several groups.
22-41
 Prior work by our group has 
demonstrated, using bacterially synthesized GST-MDA-7 protein,
32
 in the 0.25–2.0 nmol/l 
concentration in range, that GST-MDA-7 primarily caused growth arrest with little cell 
killing.  At ~20-fold greater concentrations, this cytokine causes profound growth arrest 
and tumor cell death.
32,35,36
 Our group has also demonstrated that Ad.5-mda-7 mediated 
cell death in melanoma cells is in part due to promotion of  p38 MAPK dependent 
activation of the growth arrest and DNA damage inducible genes, including GADD153, 
GADD45, and GADD34.
38
 However, in primary GBM cells, p38 MAPK signaling was 
shown to provide a protective signal.
36
 Other groups have argued that inhibition of PI3K 
signaling, but not ERK1/2 signaling, modestly promotes Ad.5-mda-7 lethality in breast and 
lung cancer cells.
39,40
 This study was designed to define more effective ways of inducing 
GBM cell death using mda-7/IL-24. This study provides data supporting the hypothesis 
that simultaneous inhibition of multiple cytoprotective pathways, including mammalian 
target of rapamycin (mTOR), PI3K, and/or mitogen-activated extracellular regulated 
kinase (MEK)1/2 signaling, facilitates lethality of mda-7/IL-24 toward GBM cells both in 
vitro and in vivo.  
88 
Delivery of therapeutic genes using Ad.5 has shown limitations in treating GBM, 
due to the need for Coxsackie adenovirus receptors (CARs) on tumor cells for virus entry. 
This work in this study evaluated the use of a tropism-modified adenovirus which uses a 
serotype 3 modification of the serotype 5 viral knob protein to facilitate delivery of mda-
7/IL-24 in a CAR-independent manner.148,147 This approach resulted in augmented 
therapeutic activity of mda-7/IL-24 in GBM cells, suggesting that combination of both 
strategies, namely inhibition of cytoprotective pathways and tropism modification, may 
provide a means of developing an improved therapy for GBMs. 
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CHAPTER 7 RESULTS:  
INHIBITORS OF MULTIPLE PROTECTIVE SIGNALING 
PATHWAYS AND Ad.5/3 DELIVERY ENHANCES MDA-7/IL-24 
KILLING 
 
7.1 Serotype Ad.5-mda-7 killing was significantly enhanced with coexpression of 
dnMEK1 and dnAKT.  Ad.5-mda-7 lethality was almost abolished with coexpression 
of activated MEK1 and AKT in primary human GBM cells 
As previously shown in the first section of this thesis, MDA-7/IL-24 has a 
profound effect, i.e. inhibition, on pro-survival signaling pathways. To further identify the 
potential pathways involved in the regulation of MDA-7/IL-24 toxicity, modulation of 
AKT and MEK1 function was performed to assess a role for the PI3K/MEK/mTOR 
pathways. GBM6 and GBM12 cells were plated in 12-well plates (~2.5 x 10
4
 cells per 
well) for 24h. Cells were then infected (all virus infections at 10 m.o.i.) with empty vector 
control virus (Ad.cmv) or virus to express MDA-7/IL-24 (Ad.mda-7). Twelve hours after 
initial infection cells were infected with viruses to express activated forms of AKT and 
MEK1 (caAKT, caMEK1), and dominant negative forms of AKT and MEK1 (dnAKT, 
dnMEK1). At 48 hours (GBM6) or 96 hours (GBM12) post initial infection, cells were 
isolated and cell viability was determined by Trypan blue exclusion assay (±SEM, n = 3). 
Upper inset of figure 8.1.1 shows the impact of expressing caAKT, caMEK1, dnAKT, and 
dnMEK1 on cell signaling.   
These results indicated that in primary human GBM cells, infection with a serotype 
5 recombinant adenovirus to express MDA-7/IL-24 (Ad.5-mda-7) was able to induce cell 
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killing that was modestly enhanced by expression of dnMEK1 or dnAKT individually; 
killing was shown to be significantly enhanced by concomitant expression of these 
inhibitory proteins.  In contrast, expression of either activated MEK1 or activated AKT 
alone was shown to significantly suppress Ad.5-mda-7 cell killing and, concomitant  
expression of these active proteins was shown to almost abolish cell killing. 
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Figure 7.1.1 Ad.5-mda-7 lethality is enhanced by combined inhibition of 
PI3K/MEK/mTOR pathways in GBM 6 cells. GBM6 cells were infected with empty 
vector control virus (Ad.5-cmv) or with viruses to express MDA-7/IL-24 (Ad.5-mda-7), 
activated forms of AKT and MEK1 (caAKT, caMEK1), and dominant negative forms of 
AKT and MEK1 (dnAKT, dnMEK1). At 48 hours (GBM6) or 96 hours (GBM12) after 
infection, cells were isolated and cell viability was determined by Trypan blue exclusion 
assay (•}SEM, n = 3). Upper inset shows the impact of expressing caAKT, caMEK1, 
dnAKT, and dnMEK1 on cell signaling.  
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Figure 7.1.2 Ad.5-mda-7 lethality is enhanced by combined inhibition of 
PI3K/MEK/mTOR pathways in GBM 12 cells. GBM12 cells were infected with empty 
vector control virus (Ad.5-cmv) or with viruses to express MDA-7/IL-24 (Ad.5-mda-7), 
activated forms of AKT and MEK1 (caAKT, caMEK1), and dominant negative forms of 
AKT and MEK1 (dnAKT, dnMEK1). At 48 hours (GBM6) or 96 hours (GBM12) after 
infection, cells were isolated and cell viability was determined by Trypan blue exclusion 
assay (•}SEM, n = 3). Upper inset shows the impact of expressing caAKT, caMEK1, 
dnAKT, and dnMEK1 on cell signaling.  
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7.2 17AAG, PD184352/PX866 and PD184352/PI-103 treatments all promote 
Ad.5mda-7/IL-24 toxicity that is abolished by upregulation of pro-survival BCL-2 
family proteins found in GBM cells. 
 The expression of pro-survival proteins of the BCL2 family, are highly upregulated 
when MEK and AKT pathways are activated. In this study, GBM6 cells were used to 
assess the role of the BCL-2 family members in modulating cell death induced by 
Ad.5mda-7/IL24. Cells were plated in 12-well plates (~2.5 x 10
4
 cells per well) for 24h. 
Cells were then infected (all virus infections at 10 m.o.i.) with empty vector control virus 
(Ad.cmv) or virus to express MDA-7/IL-24 (Ad.mda-7).  Twelve hours after initial 
infection cells were infected with viruses to express BCL-XL and MCL-1.  Cells were 
treated with 17AAG, PD184352/PX866 and PI103/PD184352 twelve hours after infection. 
Forty-eight hours after initial infection with Ad.mda-7, cells were isolated and cell viability 
was determined by trypan blue exclusion assay (±SEM, n = 3).  These results indicated that 
BCL-XL and MCL-1 over-expression led to the abolishion of the cell killing potential of 
17AAG (100 nmol/l), PD184352/PX866 (PD+PX - 1 μmol/l+100 nmol/l respectively) and 
PI-103/PD184352 (PI103+PD - 200 nmol/l+1 μmol/l respectively) when used as individual 
agents or in combination with Ad.mda-7/IL-24 (Figures 7.2.1 and 7.2.2). 
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7.2.1 BCL-2 overexpression abolishes 17AAG, PD184352/PX866 and PD184352/PI-
103 ehnacement of Ad.5mda-7/IL-24 toxicity in GBM6 cells. 
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7.2.2 MCL-1 overexpression abolishes 17AAG, PD184352/PX866 and PD184352/PI-
103 ehnacement of Ad.5mda-7/IL-24 toxicity in GBM6 cells. 
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7.3 Knockdown of mTOR expression in vitro enhanced Ad.5-mda-7 toxicity to a 
similar extent as expression of dnMEK1 and a dn-p85 PI3K subunit. 
Previous sections have indicated that the PI3K/MEK/mTOR pathways are involved 
in MDA-7/IL-24 mediated cell death. In addition, a key mechanism of MDA-7/IL-24 
tumor cell killing is the capacity of this agent to induce toxic autophagy.  In an attempt to 
demonstrate this, GBM6 cells were plated in 12-well plates (~2.5 x 10
4
 cells per well) for 
24h. Cells were then infected (all virus infections at 10 m.o.i.) with empty vector control 
virus (Ad.cmv) or virus to express MDA-7/IL-24 (Ad.mda-7) for 12 h.  In parallel, cells 
were transfected with empty vector plasmid or plasmids to express a dn-p85 PI3K subunit 
(dn-p85) and dnMEK1. Cells were also transfected with a nonspecific siSCR or a siRNA to 
specifically knockdown mTOR expression, as indicated. At 48 hours after initial infection, 
cells were isolated and cell viability was determined by Trypan blue exclusion assay 
(±SEM, n = 3).  Results indicated that combined expression of dnMEK1 and a dn-p85 
PI3K subunit led to an enhancement of Ad.5-mda-7 cell killing, similar to that seen for 
dnMEK1 or dnAKT expression (Figure 7.3). Knockdown of mTOR expression in vitro 
was also shown to enhanced Ad.5-mda-7 toxicity to a similar extent to that seen for 
dnMEK1 and a dn-p85 PI3K subunit (Figure 7.3). The inhibition of mTOR/PI3K/MEK 
together in these cells was shown to significantly reduce GBM cell viability and strongly 
enhanced Ad.5-mda-7 lethality. 
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Figure 7.3 Ad.5-mda-7 lethality is enhanced by combined inhibition of 
PI3K/MEK/mTOR pathways.  GBM6 cells were infected with empty vector control 
virus (Ad.5-cmv) or with a virus to express MDA-7/IL-24 (Ad.5-mda-7). In parallel, cells 
were transfected with empty vector plasmid or plasmids to express a dn-p85 PI3K subunit 
(dn-p85) and dnMEK1; cells were transfected with a nonspecific scrambled siRNA 
(siSCR) or an siRNA to knockdown mTOR expression, an indicated. At 48 hours after 
infection, cells were isolated and cell viability was determined by Trypan blue exclusion 
assay (―SEM, n = 3). 
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7.4 Combined inhibition of PI3K/MEK/mTOR modestly suppressed tumor growth of 
orthotopic GBM tumors in vivo and profoundly enhanced Ad.5-mda-7 tumoricidal 
capability 
In order to characterize the autophagic-inducing effects of MDA-7/IL-24 on GBM 
cells in vivo, GBM6 cells stably transfected with luciferase, were infected (all virus 
infections at 10 m.o.i.) with empty vector control virus (Ad.cmv) or virus to express MDA-
7/IL-24 (Ad.mda-7), and subsequently transfected with a siSCR and an empty vector 
plasmid or with an siRNA to knockdown mTOR expression and plasmids to express a dn-
p85 PI3K subunit and dnMEK1. Twelve hours after transfection/infection equal numbers 
of viable tumor cells were implanted into the brains of athymic mice and tumor formation 
monitored over the following 32 days by luciferase/CCD camera imaging (n = 2, ±SEM). 
In agreement with in vitro findings, results indicated that the molecular inhibition of 
mTOR/PI3K/MEK1 signaling, but not mTOR alone, was shown to modestly suppress 
tumor growth of orthotopic GBM tumors in vivo for up to 32 days after infusion of tumor 
cells into mouse brains, and profoundly enhance the tumoricidal effects of Ad.5-mda-7 
(Figure 7.4). 
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Figure 7.4 Ad.5-mda-7 lethality is enhanced by combined inhibition of 
PI3K/MEK/mTOR pathways in vivo. GBM6-luciferase cells were infected with empty 
vector control virus (Ad.5-cmv) or with viruses to express MDA-7/IL-24 (Ad.5-mda-7) and 
in parallel transfected with a siSCR and an empty vector plasmid or with an siRNA to 
knockdown mTOR expression and plasmids to express a dn-p85 PI3K subunit and 
dnMEK1. At 12 hours after transfection/infection equal numbers of viable tumor cells were 
implanted into the brains of athymic mice and tumor formation monitored over the 
following 32 days by luciferase/CCD camera imaging (n = 2, ―SEM). CMV, 
cytomegalovirus; dn, dominant negative; ERK, extracellular regulated kinase; GBM, 
glioblastoma multiforme; MEK, mitogen-activated extracellular regulated kinase. 
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7.5 Small molecule inhibitors of mTOR, PI3K and MEK1/2 signaling: 17AAG, PX866 
and PD184352 respectively, enhanced Ad.5-mda-7 toxicity in primary human GBM 
cells. This correlated closely with enhanced JNK1/2 activation and reduced 
expression of BCL-XL and MCL-1 
 Known small molecular inhibitors of pro-survival signaling cascades were used to 
further confirm previous results using molecular tools. GBM6, 12 and 14 cells were 
infected (all virus infections at 10 m.o.i.) with empty vector control virus (Ad.cmv) or virus 
to express MDA-7/IL-24 (Ad.mda-7). Twelve hours after infection, cells were treated with 
vehicle (DMSO)], PD+PX, 1 μmol/l + 100 nmol/l respectively), 17AAG (100 nmol/l). 
Twenty four and 48 hours after infection, cells were isolated and SDS-PAGE was 
performed to determine the expression of BCL-XL and MCL-1, and the phosphorylation of 
ERK1/2, p38 MAPK, JNK1-3, AKT (S473) (n = 2).  At 48 hours after infection, cells were 
isolated and cell viability was determined by Trypan blue exclusion assay (±SEM, n = 3).  
These results indicated that in GBM6 cells (expressing ERBB1 vIII), GBM12 cells 
(expressing mutant active full length ERBB1), and GBM14 cells (expressing mutant PTEN 
(phosphatase and tensin homologue on chromosome 10)), the individual drugs had modest 
(GBM6) to significant (GBM14) effects as single agents on cell viability (Figure 7.5, 
graphical panels). In all GBM cell isolates tested, PD+PX and 17AAG were shown to 
enhance the toxicity of Ad.5-mda-7 in a greater than additive fashion. In GBM6 cells 
infected with Ad.5-mda-7, inhibition of the MEK1/2 and PI3Ksignaling pathways led to 
enhanced JNK1/2, but not p38 MAPK activation, and to more tumor cell killing in vitro 
(Figure 7.5, blotting panels). Inhibition of signaling pathways and enhanced cell killing 
101 
was also closely correlated with reduced expression of the BCL-2 family proteins BCL-XL 
and MCL-1. 
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Figure 7.5 Inhibition of mTOR, PI3K, and MEK1/2 signaling enhances Ad.5-mda-7 
lethality in GBM cells. GBM6 cells were infected with Ad.5-cmv or Ad.5-mda-7 and 12 
hours after infection treated with vehicle (DMSO), 17AAG (100 nmol/l), or PD184352 
(PD, 1 μmol/l) and PX866 (100 nmol/l) (PD+PX). At 24 and 48 hours after infection, cells 
were isolated and sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) was performed to determine the expression of BCL-XL and MCL-1, and the 
phosphorylation of ERK1/2, p38 MAPK, JNK1-3, AKT (S473) (n = 2). GBM cells were 
infected with empty vector (Ad.5-cmv) or to express MDA-7/IL-24 (Ad.5-mda-7) and 12 
hours after infection treated with vehicle (VEH) dimethyl sulfoxide (DMSO)], 
PD184352+PX866 (PD+PX, 1 μmol/l + 100 nmol/l), 17AAG (100 nmol/l). At 48 hours 
after infection, cells were isolated and cell viability was determined by Trypan blue 
exclusion assay (―SEM, n = 3).  
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7.6 Treatment of GBM6 cells with multi-PI3K inhibitor PI-103 in combination with 
PD184352, had a greater killing effect than PD184352 in combination with PX866, 
without further activation of JNK1-3 
In this study, GBM6 cells were plated as single cells in sextuplicate, 12 hours after 
plating; cells were infected with Ad.5-cmv or Ad.5-mda-7. Twelve hours after initial 
infection, cells were treated with vehicle (DMSO), PD184352 (1 μmol/l) + PI-103 (200 
nmol/l) (PD+PI), PD (1 μmol/l) + PX866 (100 nmol/l), PD+PX, or 17AAG (100 nmol/l). 
Forty eight hours after initial infection, the growth media was removed from treated cells 
and replaced with fresh media lacking drugs. Colonies of >50 cells were permitted to form 
over the following ~20 days, followed by fixing, staining, and counting (±SEM, n = 3).  In 
conjunction with this work, GBM6 cells were plated in 12-well plates (~2.5 x 10
4
 cells per 
well) for 24h and then infected (all virus infections at 10 m.o.i.) with empty vector control 
virus (Ad.cmv) or virus to express MDA-7/IL-24 (Ad.mda-7). Twelve hours after infection, 
cells were treated with vehicle (DMSO), rapamycin (rap, 100 nmol/l), PI-103 (200 nmol/l), 
PD (1 μmol/l), or PI-103+PD. Forty eight hours after initial infection, cells were isolated 
and cell viability was determined by Trypan blue exclusion assay (±SEM, n = 3) (Figure 
7.6.1). In addition, GBM6 cells were infected with Ad.5-cmv or Ad.5-mda-7 and 12 hours 
after infection treated with vehicle (DMSO), rap (100 nmol/l), or PD (1 μmol/l) and PI-103 
(200 nmol/l) (PI-103 + PD). Twenty four hours after infection, cells were isolated and 
SDS-PAGE performed to determine the expression of BCL-XL and MCL-1, and the 
phosphorylation of ERK1/2, p38 MAPK, JNK1-3, AKT (S473), mTOR (S2446), and p70 
S6K (T389) (n = 2) (Figure 7.6.3). 
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Treatment of GBM6 cells with PI-103+PD was shown to induce a significantly 
greater decrease in tumor cell viability/growth than was observed using PD+PX in a 
colony assay (Figure 7.6.2). PI-103+PD treatment was shown to inhibit the 
phosphorylation of AKT, mTOR, and p70 S6K but unlike PD+PX treatment, did not cause 
further activation of JNK1-3 (Figure 7.6.3). 
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Figure 7.6.1 Inhibition of mTOR, PI3K, and MEK1/2 signaling enhances Ad.5-mda-7-
induced inhibition of growth/survival in GBM cells – Trypan Blue Assay.  GBM6 cells 
were infected with Ad.5-cmv or Ad.5-mda-7 and 12 hours after infection treated with 
vehicle (DMSO), rapamycin (rap, 100 nmol/l), PI-103 (200 nmol/l), PD184352 (PD, 1 
μmol/l), or PI-103+PD. At 48 hours after infection, cells were isolated and cell viability 
was determined by Trypan blue exclusion assay (―SEM, n = 3). 
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Figure 7.6.2 Inhibition of mTOR, PI3K, and MEK1/2 signaling enhances Ad.5-mda-7-
induced inhibition of growth/survival in GBM cells – Colony Formation Assay. GBM6 
cells were plated as single cells in sextuplicate and 12 hours after plating were infected 
with Ad.5-cmv or Ad.5-mda-7. At 12hour(s) after infection cells were treated with vehicle 
(DMSO), PD184352 (PD, 1 μmol/l) + PI-103 (200 nmol/l) (PD+PI), PD184352 (PD, 1 
μmol/l) + PX866 (100 nmol/l) (PD+PX), or 17AAG (100 nmol/l). At 48 hours after 
infection, the growth media was removed and replaced with new media lacking drugs. 
Colonies of >50 cells were permitted to form over the following ~20 days, followed by 
fixing, staining, and counting (―SEM, n = 3). 
 
 
 
 
 
  
* 
* * 
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Figure 7.6.3 Inhibition of mTOR, PI3K, and MEK1/2 signaling enhances Ad.5-mda-7 
lethality in GBM cells. GBM6 cells were infected with Ad.5-cmv or Ad.5-mda-7 and 12 
hours after infection treated with vehicle (DMSO), rapamycin (rap, 100 nmol/l), or 
PD184352 (PD, 1 μmol/l) and PI-103 (200 nmol/l) (PD+PI-103). At 24hour(s) after 
infection cells were isolated and SDS-PAGE performed to determine the expression of 
BCL-XL and MCL-1, and the phosphorylation of ERK1/2, p38 MAPK, JNK1-3, AKT 
(S473), mTOR (S1221), and p70 S6K (T389) (n = 2). 
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7.7 Inhibition of JNK1-3 blocks MDA-7/IL-24 toxicity and inhibited the promotion of 
cell death by small molecule kinase inhibitors 
Previous results had suggested that JNK1-3 activation plays a key role in MDA-
7/IL-24-induced lethality. To further expand upon these findings GBM6 cells were plated 
in 12-well plates (~2.5 x 10
4
 cells per well) for 24h. Cells were then infected (all virus 
infections at 10 m.o.i.) with  empty vector control virus (Ad.cmv) or virus to express 
MDA-7/IL-24 (Ad.mda-7) and 12 hours after infection treated with vehicle (DMSO) or 
JNK inhibitory protein (JNK-IP). Thirty minutes after threatment with the JNK-IP, cells 
were treated with vehicle (DMSO), PD+PX (1 μmol/l+100 nmol/l respectively), PI-
103+PD (200 nmol/l+1 μmol/l respectively) or 17AAG (100 nmol/l). Forty eight hours 
after initial infection, cells were isolated and cell viability was determined by TUNEL 
assay (±SEM, n = 3). These results indicated that the inhibition of JNK1-3 was able to 
block MDA-7/IL-24 mediated toxicity, in addition to blocking the enhancement of MDA-
7/IL-24 toxicity by the small molecule kinase inhibitors (Figure 7.7). 
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Figure 7.7 Inhibition of JNK1-3 blocks MDA-7/IL-24 toxicity and any promotion of 
toxicity by small molecule kinase inhibitors. 
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7.8 17AAG, Rapamycin, PD184352/PX866 and PD184352/PI-103 treatments all 
promote Ad.5mda-7/IL-24 toxicity through the intrinsic apoptotic pathway in GBM 
cells 
 MDA-7/IL-24 treated GBM cells, in combination with the molecular inhibitors 
used, was shown to enhance MDA-7/IL-24-induced downregulation of pro-survival 
proteins (BCL-XL, MCL-1 and AKT1/2) as well as inducing the upregulation of stress 
induced signaling cascades (JNK1-3, p38-MAPK), leading to cell death.  A potential role 
for apoptosis (Intrinsic/Extrinsic pathway(s)) in cell death was investigated.  GBM6 cells 
were infected with Ad.5-cmv or Ad.5-mda-7 in combination with viruses to express XIAP, 
BCL-XL, dominant negative (dn) caspase 9, or c-FLIP-s. Twelve hours after infection, 
cells were treated with vehicle (DMSO), or PD (1 μmol/l) + PX (100 nmol/l) (PD+PX) 
(Figure 7.8.1); 17AAG (100 nmol/l) (Figure 7.8.2); rap (100 nmol/l), or PI-103 (200 
nmol/l) + PD (1 μmol/l) (PI-103+PD) (Figure 7.8.3). Forty eight hours after initial 
infection cells were isolated and cell viability was determined by Trypan blue exclusion 
assay (±SEM, n = 3).  The results from this study indicated that inhibitors of the intirisic 
pathway of apoptosis (XIAP, BCL-XL, dn caspase 9) induced less cell death in the 
presence of Ad.mda-7/IL-24, when compared to cell death seen in response to inhibiton of 
proteins involved in the extrinsic pathway of apoptosis (c-FLIP-s)  (Figures 7.8.1-7.8.3). 
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Figure 7.8.1 Activation of the intrinsic pathway plays a key role in the facilitation of 
Ad.5-mda-7 toxicity by kinase inhibitors PD+PX. GBM6 cells were infected with Ad.5-
cmv or Ad.5-mda-7 in combination with viruses to express XIAP, BCL-XL, dominant 
negative (dn) caspase 9, or c-FLIP-s, and 12 hours after infection treated with vehicle 
[VEH; dimethyl sulfoxide (DMSO)], or PD184352 (PD, 1 μmol/l) + PX866 (100 nmol/l) 
(PD+PX). At 48 hours after infection cells were isolated and cell viability was determined 
by Trypan blue exclusion assay (―SEM, n = 3).  
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Figure 7.8.2 Activation of the intrinsic pathway plays a key role in the facilitation of 
Ad.5-mda-7 toxicity by kinase inhibitor 17AAG. GBM6 cells were infected with Ad.5-
cmv or Ad.5-mda-7 in combination with viruses to express XIAP, BCL-XL, dn-caspase 9, 
or c-FLIP-s, and 12 hours after infection treated with VEH (DMSO), or 17AAG (100 
nmol/l). At 48 hours after infection cells were isolated and cell viability was determined by 
Trypan blue exclusion assay (―SEM, n = 3).  
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Figure 7.8.3 Activation of the intrinsic pathway plays a key role in the facilitation of 
Ad.5-mda-7 toxicity by kinase inhibitors Rapamycin and PI-103+PD.  GBM6 cells 
were infected with Ad.5-cmv or Ad.5-mda-7 in combination with viruses to express XIAP, 
BCL-XL, dn-caspase 9, or c-FLIP-s, and 12 hours after infection treated with VEH 
(DMSO), rapamycin (100 nmol/l), or PI-103 (200 nmol/l) + PD184352 (PD, 1 μmol/l) (PI-
103+PD). At 48 hours after infection cells were isolated and cell viability was determined 
by Trypan blue exclusion assay (―SEM, n = 3).  
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7.9 Infection of tumor cells with Ad.5-mda-7 was shown to increase PERK 
phosphorylation and LC3-II processing, without further enhancement when Ad.5-
mda-7 was combined with the small molecule inhibitors, 17AAG or PD184352/PX866 
Previous studies have demonstrated that GST-MDA-7 is able to induce GBM cell 
death in a PERK-dependent fashion, attributed to increased levels of autophagy.
35,36
 
GBM6, 12 and 14 cells were infected (all virus infections at 10 m.o.i.) with  empty vector 
control virus (Ad.cmv) or virus to express MDA-7/IL-24 (Ad.mda-7) and 12 hours after 
infection treated with vehicle (DMSO)], PD (1 μmol/l) + PX (100 nmol/l) (PD+PX), or 
17AAG (100 nmol/l). Cells were isolated 24 and 48 hours after infection and SDS-PAGE 
and immunoblotting was performed upon cell lysates to assess the phosphorylation of 
PERK and the conversion of LC3 to LC3-II (n = 3).  These results indicated that as a single 
agent, 17AAG increased PERK phosphorylation and LC3-II processing, whereas PD+PX 
treatment reduced basal PERK phosphorylation and LC3-II processing (Figure 7.9). 
Infection of tumor cells with Ad.5-mda-7 alone was shown to increase PERK 
phosphorylation and LC3-II processing. 
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Figure 7.9 Inhibition of signaling pathways enhances Ad.5-mda-7-induced autophagy, 
but does not promote additional activation of PERK. GBM6 cells were infected with 
Ad.5-cmv or Ad.5-mda-7 and 12 hours after infection treated with vehicle [VEH; dimethyl 
sulfoxide (DMSO)], PD184352 (PD, 1 μmol/l) + PX866 (100 nmol/l) (PD+PX), or 
17AAG (100 nmol/l). Cells were isolated 24 and 48 hours after infection and  sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis and immunoblotting was performed to 
assess the phosphorylation of PERK and the conversion of LC3 to LC3-II (n = 3).  
 
 
 
 
 
 
 
 
 
116 
7.10 17AAG or PD184352/PX866 treatments enhance Ad.5-mda-7 induced autophagy 
by causing an increase in autophagic flux 
  To further assess a role of these small molecular inhibitors in the induction of 
autophagy, the formation of L3C-GFP vesicles was assessed. GBM6 cells were plated in 4-
well chamber slides, then infected with Ad.5-cmv or Ad.5-mda-7 and in parallel transfected 
with a plasmid to express LC3-GFP and with either a siSCR or an siRNA to knock down 
Beclin1 (siBeclin1). Twelve hours after infection, cells were treated with vehicle (DMSO), 
17AAG, or PD+PX.  Twelve hours after drug treatment cells were examined using a 
fluorescent microscope (×40 magnification) for the formation of intense GFP-staining 
vesicles (±SEM, n = 3).  These results indicated that infection of GBM6 cells with Ad.5-
mda-7 was shown to increase the number of autophagic vesicles in cells, judged using the 
transfected LC3-GFP construct (Figure 7.10). The signal transduction pathway inhibitory 
drugs 17AAG and PD+PX, were shown to increase Ad.5-mda-7-induced autophagy levels. 
Although the PD+PX treatment, which will inhibit MEK1 and PI3K respectively, was 
shown to suppress the detection of LC3-II via immunoblotting (Figure 7.9), the drug 
combination increased autophagy as judged by the formation of punctate LC3-GFP 
staining bodies. This result suggests that the combined inhibition of MEK1/2 and PI3K can 
lead to a large increase in autophagic flux. 
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Figure 7.10 Inhibition of signaling pathways enhances Ad.5-mda-7-induced 
autophagy, without promoting the additional activation of PERK. GBM6 cells in 4-
well chambered slides were infected with Ad.5-cmv or Ad.5-mda-7 and in parallel 
transfected with a plasmid to express LC3-GFP and with either a scrambled siRNA 
(siSCR) or an siRNA to knockdown Beclin1 (siBeclin1). At 12 hours after infection cells 
were treated with vehicle (DMSO), 17AAG, or PD+PX. At 12 hours after drug treatment 
cells were examined using a fluorescent microscope (×40 magnification) for the formation 
of intense GFP-staining vesicles (―SEM, n = 3). 
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7.11 Knockdown of Beclin1 or ATG5 abolished Ad.5-mda-7 toxicity and significantly 
reduced the abilities of 17AAG and to a lesser extent PD184352/PX866 exposure to 
cause cell death 
Previous studies have demonstrated that GST-MDA-7 was able to induce autophagy and 
cell death in GBM cells that was blocked by knock down of Beclin1 or ATG5 
expression.
35
 The presence of a similar role for these proteins in GBM cells infected with 
Ad.mda-7/IL-24was assessed. GBM6 cells were infected with Ad.5-cmv or Ad.5-mda-7 
and, in parallel, transfected with either siSCR or siRNA molecules to knock down siATG5 
or siBeclin1. Twelve hours after infection, the cells were treated with vehicle (DMSO), PD 
(1 μmol/l) + PX (100 nmol/l) (PD+PX), or 17AAG (100 nmol/l). Forty eight hours after 
infection, cells were isolated and cell viability was determined by Trypan blue exclusion 
assay (±SEM, n = 3). Results indicated that knock down of Beclin1 or ATG5 abolished 
Ad.5-mda-7 toxicity and significantly reduced 17AAG mediated cell death.  PD+PX 
induced cell death was also reduced. (Figure 7.11). Thus, the ability of GBM cells to 
respond to MDA-7/IL-24 expression with increased autophagy plays a key role in both 
Ad.5-mda-7 toxicity as a single agent, and when combined with signal transduction 
modulating drugs (Figures 7.9-7.11). 
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Figure 7.11 Knockdown of Beclin1 or ATG5 abolished Ad.5-mda-7 toxicity and 
significantly reduced the abilities of 17AAG and to a lesser extent PD184352/PX866 
exposure to cause cell death. GBM6 cells were infected with Ad.5-cmv or Ad.5-mda-7 
and in parallel transfected with either a scrambled siRNA (siSCR) or siRNA molecules to 
knockdown ATG5 (siATG5) or Beclin1  siBeclin1). At 12 hours after infection cells were 
treated with vehicle (DMSO), PD184352 (PD, 1 μmol/l) + PX866 (100 nmol/l) (PD+PX), 
or 17AAG (100 nmol/l). At 48 hours after infection cells were isolated and cell viability 
was determined by Trypan blue exclusion assay (―SEM, n = 3).  
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7.12 MDA-7/IL-24 sensitizes GBM cells to radiation therapy and enhances survival in 
vivo.  
MDA-7/IL-24, has demonstrated tumor cell–specific killing and is also able to 
radiosensitize malignant glioma cells.
33-36,133
 It has been demonstrated in our lab that 
specific signaling pathways may provide protection from mda-7/IL-24–induced cell death., 
This current study aimed to assess the role of targeting these multiple-specific 
cytoprotective signaling pathways in combination with mda-7/Il-24 treatment on human 
and rodent GBM both in vitro and in vivo.  GBM14 cells, lacking functional PTEN, were 
implanted into the brains of athymic nude mice. Fourteen days after implantation, the 
tumors were infused with Ad.5-cmv or Ad.5-mda-7 and 48 hours after infection the head of 
each animal was irradiated twice with 4 Gy, irradiations were 24h apart.  Animals were 
monitored daily and killed when approaching death. Survival of animals was plotted as a 
percentage of animals alive on any given day (±SEM, n = 2). Inset panel: 2 days after 
infection, animal brains were isolated and TUNEL (terminal deoxynucleotidyl transferase 
dUTP nick-end labeling) stained for apoptotic cells.  
Prior studies had shown that in vivo infection of an orthotopic tumor containing 
GBM6 or GBM12 cells with Ad.5-mda-7 was able to prolong animal survival. Results 
presented here indicated that GBM14 cells which lack PTEN functionality allowed 
prolonged animal survival when infected with Ad.5-mda-7 (Figure 7.12.1). In agreement 
with results seen in GBM6 and GBM12 tumors, GBM14 tumors infected with Ad.5-mda-7 
to express MDA-7/IL-24 in this study, exhibited elevated levels of apoptosis, as detected 
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by the TUNEL assay, enhanced β-galactosidase staining, and a reduced levels of Ki67 and 
CD133 staining (Figure 7.12.2). 
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7.12.1 Ad.5-mda-7/IL-24 sensitizes GBM 14 cells to radiation therapy and enhances 
survival in vivo. GBM14 cells were implanted into the brains of athymic nude mice and 
14 days after implantation tumors were infused with Ad.5-cmv or Ad.5-mda-7 and 48 hours 
after infection the heads of each animal were irradiated (2 × 4 Gy, once every 24 hours). 
Animals were monitored daily and when approaching death were killed and survival of 
animals is plotted as a percentage of animals alive on any given day (―SEM, n = 2).  
Upper panel: 2 days after infection, animal brains were isolated and TUNEL (terminal 
deoxynucleotidyl transferase dUTP nick-end labeling) stained for apoptotic cells. 
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7.12.2 Ad.5-mda-7/IL-24 sensitizes GBM 14 cells to radiation therapy and enhances 
survival in vivo. 
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7.13 MDA-7/IL-24 and temozolomide interact in at least an additive fashion to kill 
primary human GBM cells in short term viability assays.  
In an attempt to further enhance the apoptotic potential of MDA-7/IL-24, 
experiments were performed to assess whether Ad.5-mda-7 lethality could be enhanced by 
temozolomide (TMZ), an established GBM therapeutic agent. GBM6, GBM12, and 
GBM14 cells were infected with Ad.5-cmv or Ad.5-mda-7. Twelve hours after infection 
cells were treated with vehicle (DMSO)] or increasing concentrations of TMZ. Forty eight 
hours after infection, cells were isolated and cell viability was determined by TUNEL 
assay (±SEM, n = 3). These results indicated that TMZ was able to induce cell killing in a 
dose-dependent manner. In addition, this cell killing potential was increased by the 
expression of MDA-7/IL-24 in these cells (Figure 7.13). 
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Figure 7.13 Temozolomide (TMZ) potentiates Ad.5-mda-7 lethality in GBM cells. 
GBM6, GBM12, and GBM14 cells were infected with Ad.5-cmv or Ad.5-mda-7, and 12 
hours after infection cells were treated with vehicle [dimethyl sulfoxide (DMSO)] or 
increasing concentrations of TMZ. At 48 hours after infection, cells were isolated and cell 
viability was determined by TUNEL assay (―SEM, n = 3).  
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7.14 Radiation, MDA-7/IL-24 and temozolomide interact in a greater than additive 
fashion to kill primary human GBM cells  
In order to examine the interaction(s) of TMZ and radiation and MDA-7/IL-24 in 
GBM cells, GBM6, GBM12, and GBM14 cells were infected with Ad.5-cmv or Ad.5-mda-
7. Twelve hours after infection, the cells were treated with vehicle (DMSO) or increasing 
concentrations of TMZ. Twenty four hours after virus infection cells were irradiated (4 
Gy). Forty eight hours after infection, cells were isolated and cell viability was determined 
by TUNEL assay (±SEM, n = 3). These results indicated that a combination of radiation, 
MDA-7/IL-24, and TMZ were able to interact in at least an additive fashion to kill primary 
human GBM cells (Figure 7.14). 
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Figure 7.14 Temozolomide (TMZ) potentiates Ad.5-mda-7 lethality and 
radiosensitivity. GBM6, GBM12, and GBM14 cells were infected with Ad.5-cmv or Ad.5-
mda-7, and 12 hours after infection cells were treated with vehicle (DMSO) or increasing 
concentrations of TMZ. At 24 hours after virus infection cells were irradiated (4 Gy). At 48 
hours after infection, cells were isolated and cell viability was determined by TUNEL 
assay (―SEM , n = 3).  
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7.15 Radiation, MDA-7/IL-24 and temozolomide interact in a greater than additive 
fashion to kill primary human GBM cells in colony formation assays. 
In addition to short term assays of cell death, assessment of longer term colony 
formation was performed. GBM6, GBM12, and GBM14 cells were plated as single cells 
and were infected with Ad.5-cmv or Ad.5-mda-7, 12 hours after infection cells were treated 
with vehicle (DMSO) or increasing concentrations of TMZ. Twenty four hours after virus 
infection cells were irradiated (4 Gy). Forty eight hours after infection, media was replaced 
with fresh media lacking vehicle/drugs. Colonies of >50 cells were permitted to form over 
the following ~20 days, followed by fixing, staining, and counting of colonies (±SEM, n = 
3). Similar results as seen in previous short-term death assays were attained (Figure 7.14), 
indicating a greater than additive induction of cell killing by the combination of these 
agents (Figure 7.15). 
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Figure 7.15 Temozolomide (TMZ) potentiates Ad.5-mda-7 lethality and 
radiosensitization. GBM6 and GBM14 cells were plated as single cells and were infected 
with Ad.5-cmv or Ad.5-mda-7, and 12 hours after infection cells were treated with vehicle 
(DMSO) or increasing concentrations of TMZ. At 24 hours after virus infection cells were 
irradiated (4 Gy). At 48 hours after infection, the media was replaced with media lacking 
vehicle/drugs. Colonies of >50 cells were permitted to form over the following ~20 days, 
followed by fixing, staining, and counting (―SEM,  n = 3).  
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7.16 A tropism-modified type 5/3 adenovirus infects GBM cells in a CAR independent 
fashion and to a greater extent than a serotype 5 virus in vivo.  
Biopsies from human GBM tumors in situ have been reported to express low levels of 
Coxsackievirus and adenovirus receptors (CARs), resulting in an inability of these cells to 
be infected with a serotype 5 adenovirus.
30
 In an attempt to circumvent this problem, a new 
recombinant adenovirus to express MDA-7/IL-24 that comprises the tail and shaft domains 
of a serotype 5 virus and the knob domain of a serotype 3 virus was developed. 
147,148
 
GBM6 (CAR+++) (Figure 7.16.1) and U87-MG (CAR+) (Figure 7.16.2) cells were 
infected with viruses expressing a luciferase gene, Ad.5-luc or with tropism-modified 
viruses Ad.5/3-luc, Ad.5-rgd-luc, Ad.5-D-rgd-luc and Ad.5-pK7-luc at, 10 m.o.i, as 
indicated (rgd motif binds to integrins; pK7 7 x lysine residues equating to electrostatic 
binding to cells). Cells were lysed 48 hours after infection and the luciferase activity was 
measured in triplicate (±SEM, n = 3). Upper blot: GBM6/U87 cells were infected with 
Ad.5-cmv, Ad.5/3-cmv, Ad.5-mda-7 or Ad.5/3-mda-7 (10 MOI). Cells were isolated 24 
hours after infection and MDA-7/IL-24 protein levels determined (n = 2). Results indicated 
that the serotype 5/3 virus were able to infect GBM cells in a CAR-independent fashion 
and to a greater extent than a serotype 5 virus, these results were also evident in GBM6 
cells that express significant levels of CAR (Figure 7.16.1). This increased infectivity was 
also shown to correlate with elevated levels of MDA-7/IL-24 expression (Figure 7.16.1, 
blotting panel). Of particular note, a recent study claimed that a serotype 5 virus with a 
“double RGD” knob modification to permit infection via binding to cell surface integrin 
131 
proteins, enhanced MDA-7/IL-24 delivery to GBM cells over a serotype 5 virus in vitro 
and in vivo.
140
 The results presented here Figure 7.16.1, indicated that a serotype 5 virus 
with a “double RGD” knob modification was able to enhance gene delivery to GBM cells 
over a serotype 5 virus. However, the “double RGD” virus was shown to weakly infect 
GBM cells when compared to results seen for the serotype 5/3 virus. 
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Figure 7.16.1 A tropism-modified type 5/type 3 adenovirus infects GBM 6 cells more 
readily than a type 5 adenovirus. GBM6 (CAR+++) cells were infected with Ad.5-luc or 
with tropism-modified viruses Ad.5/3-luc, Ad.5-rgd-luc, Ad.5-D-rgd-luc, Ad.5-pK7-luc at 
10 MOI, as indicated. Cells were lysed 48 hours after infection and the luciferase activity 
was measured in triplicate (―SEM, n = 3). Upper blot: GBM6 cells were infected with 
Ad.5-cmv, Ad.5/3-cmv, Ad.5-mda-7 or Ad.5/3-mda-7 (10 MOI). Cells were isolated 24 
hours after infection and MDA-7/IL-24 protein levels determined (n = 2). 
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Figure 7.16.2 A tropism-modified type 5/type 3 adenovirus infects U87 cells more 
readily than a type 5 adenovirus. U87-MG (CAR+) cells were infected with Ad.5-luc or 
with tropism-modified viruses Ad.5/3-luc, Ad.5-rgd-luc, Ad.5-D-rgd-luc, Ad.5-pK7-luc at 
10 MOI, as indicated. Cells were lysed 48 hours after infection and the luciferase activity 
was measured in triplicate (―SEM, n = 3). Upper blot: U87-MG cells were infected with 
Ad.5-cmv, Ad.5/3-cmv, Ad.5-mda-7 or Ad.5/3-mda-7 (10 MOI). Cells were isolated 24 
hours after infection and MDA-7/IL-24 protein levels determined (n = 2). 
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7.17 In a colony-formation assay, infection of GBM6, GBM12 and U87-MG cells with 
Ad.5/3-mda-7 caused a greater reduction in cell survival than cells infected with Ad.5-
mda-7 
Given that Ad.5/3-mda-7 was able to induce a greater virus infection and MDA-7/IL-24 
expression in GBM6, GBM12 and U87-MG cells, in comparison with Ad.5-mda-7, the 
potential of Ad.5/3-mda-7 in reducing colony formation to a greater extent than Ad.5-mda-
7 in these cells was assessed. GBM6, GBM12, and U87-MG cells were plated in 
sextuplicate as single cells and were infected with Ad.5-cmv or Ad.5-mda-7 or with 
tropism-modified viruses Ad.5/3-cmv or Ad.5/3-mda-7 at 0–50 m.o.i. Colonies of >50 cells 
were permitted to form over 14–20 days, followed by fixing, staining, and counting of 
colonies. Data in this section are presented as the real percentage reduction in colony 
formation, subtracting the effect of Ad.cmv (5 or 5/3) infection (±SEM, n = 3).  The results 
indicated that, in colony-formation assays, infection of GBM6, GBM12, and U87-MG 
cells with a serotype 5/3 adenovirus to express MDA-7/IL-24 (Ad.5/3-mda-7) caused a 
significant  (*P < 0.05) reduction when compared to cell survival per active virus particle, 
following infection using a serotype 5 adenovirus (Ad.5-mda-7) (Figure 7.17). 
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Figure 7.17 A tropism-modified type 5/3 adenovirus infects GBM6, GBM12 and U87-
MG cells more readily than a type 5 adenovirus, in a colony formation assay, to 
generate a greater cytotoxic effect. GBM6, GBM12, and U87-MG cells were plated in 
sextuplicate as single cells and were infected with Ad.5-cmv or Ad.5-mda-7 or with 
tropism-modified viruses Ad.5/3-cmv or Ad.5/3-mda-7 at 0–50 multiplicity of infection 
(MOI). Colonies of >50 cells were permitted to form over 14–20 days, followed by fixing, 
staining, and counting. Data are presented as the real percentage reduction in colony 
formation subtracting the effect of Ad.cmv (5 or 5/3) infection (―SEM, n = 3) *P < 0.05 
greater than Ad.5-mda-7 infection. 
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7.18 A tropism-modified type 5/3 adenovirus infects GBM cells more readily than a 
type 5 adenovirus, and enhances tumor killing in vivo.  
We next determined whether infection of pre-formed tumors with Ad.5/3-mda-7 
caused a greater reduction in tumor growth than infection with Ad.5-mda-7.  GBM6 cells 
stably expressing luciferase were implanted into the brains of athymic nude mice. Fourteen 
days after implantation tumors were infused with Ad.5-cmv or Ad.5-mda-7, or Ad.5/3-cmv 
or Ad.5/3-mda-7. The tumors in situ were imaged using a Xenogen CCD system and the 
light intensity quantified before and for 18 days following adenovirus infusion (±SEM, n = 
2). These results indicated that infection of pre-formed GBM6 tumors with Ad.5-mda-7 
induced a significant reduction (*P < 0.05), in tumor growth when compared to Ad.5-cmv 
treated cells  Further, infection of pre-formed GBM6 tumors with Ad.5/3-mda-7 caused a 
significant reduction (#P < 0.05) in tumor growth when compared to infection with Ad.5-
mda-7 (Figure 7.18.1). In isolated tumor sections, taken at 2 and 7 days after infection, it 
was noted that Ad.5/3-mda-7 caused a greater and more rapid induction in tumor apoptosis 
than Ad.5-mda-7 (Figure 7.18.2). statistics * and # 
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Figure 7.18.1 A tropism-modified type 5/3 adenovirus infects GBM6 cells more 
readily than a type 5 adenovirus, and enhances tumor killing in vivo. GBM6 cells that 
stably express luciferase were implanted into the brains of athymic nude mice and 14 days 
after implantation tumors were infused with Ad.5-cmv or Ad.5-mda-7, or Ad.5/3-cmv or 
Ad.5/3-mda-7. The tumors in situ were imaged using a Xenogen CCD system and the light 
intensity quantified before and for 18 days following adenovirus infusion (―SEM, n = 2). 
*P < 0.05 less than corresponding Ad.5-cmv treated cells; #P < 0.05 less than Ad.5-mda-7 
value. 
 
 
Ad.5/3-cmv 
Ad.5/3-mda-7 
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Figure 7.18.2 In isolated GBM6 tumor sections, at 2 and 7 days after infection, 
Ad.5/3-mda-7 caused a greater and more rapid induction of tumor apoptosis than 
Ad.5-mda-7 
 
Ad.5-mda-7 
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7.19 Ad.5/3-mda-7 is more effective at killing and reducing rodent GL261 glioma 
viability in vitro and in vivo. 
We have also used GL261 mouse glioblastoma cells to confirm our in vivo studies using 
the serotype 5 and 5/3 forms of Ad.mda-7/IL-24, in immune competent mice, GL261 cells 
were infected with Ad.5-cmv or Ad.5-mda-7 or with Ad.5/3-cmv or Ad.5/3-mda-7 at 20 or 
80 MOI. Forty eight hours after infection, cells were isolated and cell viability was 
determined by Trypan blue dye exclusion assay (±SEM, n = 3).  These results indicated 
that Ad.5/3-mda-7 was able to induce significantly more cell death (*P < 0.05), in GL261 
cells than Ad.5-mda-7 when cells were infected with virus at either 20 or 80 m.o.i. Indeed 
GL261 appeared resistant to serotype 5 virus infections (Figure 7.19.1).  To assess whether 
these results would translate to an animal model, black C57 mice were implanted with 
GL261 cells stably expressing luciferase. Fourteen days post implantation; tumors were 
infused with Ad.5/3-cmv or Ad.5/3-mda-7. Tumors were imaged in situ using a Xenogen 
CCD system and the light intensity quantified before, and 6 days following, adenovirus 
infusion (n = 2) showing a dramatic reduction of tumor growth (light intensity) (Figure 
7.19.2). Six days after virus infusion, mouse brains were isolated and 
immunohistochemistry performed to detect the levels of Ki67, CD131 and TUNEL 
(terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining (n = 2).  
Following suit with our in vitro data, the levels of proliferation marker, Ki67, and 
progenitor cell marker, CD131 where significantly reduced.  In addition, Ad.5/3-mda-7/IL-
24 increased the number of TUNEL positive cells as well as exhibiting negative effects on 
the morphology of these tumor cells (H/E staining) (Figure 7.19.3). 
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Figure 7.19.1 Ad.5/3-mda-7 is more effective at killing and reducing rodent GL261 
glioma viability in vitro. GL261 cells were infected with Ad.5-cmv or Ad.5-mda-7 or with 
Ad.5/3-cmv or Ad.5/3-mda-7 at 20 or 80 multiplicity of infection (MOI). At 48 hours after 
infection, cells were isolated and cell viability was determined by Trypan blue dye 
exclusion assay (―SEM, n = 3). *P < 0.05 greater than Ad.5-mda-7 value.  
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Figure 7.19.2 Ad.5/3-mda-7 is more effective at killing and reducing rodent GL261 
glioma viability in vivo.  C57 black mice were implanted with GL261 cells stably 
expressing luciferase. At 14 days after implantation tumors were infused with Ad.5/3-cmv 
or Ad.5/3-mda-7. The tumors in situ were imaged using a Xenogen CCD system and the 
light intensity quantified before and 6 days following adenovirus infusion (n = 2).  
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Figure 7.19.3 Ad.5/3-mda-7 is more effective at killing and reducing immune 
competent rodent GL261 glioma viability in vivo. C57 black mice were implanted with 
GL261 cells stably expressing luciferase. At 14 days after implantation tumors were 
infused with Ad.5/3-cmv or Ad.5/3-mda-7. Six days after virus infusion mouse brains were 
isolated and immunohistochemistry performed to detect the levels of Ki67, CD131, and 
TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling) staining (n = 2) 
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CHAPTER 8 DISCUSSION:  
INHIBITORS OF MULTIPLE PROTECTIVE SIGNALING 
PATHWAYS AND Ad.5/3 DELIVERY ENHANCES MDA-7/IL-24 
KILLING 
 
This study has focused on developing enhanced therapies for the treatment of 
GBM, a tumor that has been characterized with a rapid progression, with no treatment 
providing a long-term clinical benefit.1 To achieve this objective, we utilized mda-7/IL-24, 
which has been shown by our group and others to have tumor cell–specific killing and 
radiosensitization abilities in malignant glioma cells.
33-36,142
 Based upon previous 
observations that have illustrated specific signaling pathways which might provide 
protection from mda-7/IL-24–induced toxicity, the current study explored approaches 
aimed at targeting multiple-specific cytoprotective signaling pathways in combination with 
mda-7/Il-24 on human and rodent GBM both in vitro and in vivo. The studies presented in 
this thesis highlight combinations of clinically relevant protein and lipid kinase inhibitors 
that increase MDA-7/IL-24 toxicity. In addition, a tropism-modified serotype Ad.5/3 was 
used as a means of enhancing the therapeutic delivery of MDA-7/IL-24 for GBM’s.  
Infection of GBM cells with a dose of Ad.5-mda-7 virus particles able to cause 
modest levels of toxicity ~48 hours after exposure, correlated with the activation of the 
stress induced JNK1/2 and p38 MAPK pathways as well as the phosphorylation of PERK. 
In contrast, Ad.5-mda-7 suppressed pro-survival ERK1/2, AKT, mTOR, and p70 S6K 
signaling. Multiple studies using a number of toxic stimuli have been documented, 
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showing that prolonged JNK1-3 and/or p38 MAPK activation in a wide variety of cell 
types can trigger cell death.
143-145
 It is also well established that the balance between the 
readouts of ERK1/2 and JNK1-3 signaling can represent a general key homeostatic 
mechanism that regulates cell survival versus cell death processes.
143-145
 Prior studies in 
vitro and in vivo treating primary human GBM cells with GST-MDA-7 and Ad.5-mda-7 
have demonstrated that JNK1-3 signaling represents a key pro-apoptotic signal generated 
by MDA-7/IL-24 exposure and the initial hypothesis in this study was that inhibition of 
ERK/AKT/mTOR signaling would promote the toxicity of Ad.5-mda-7, primarily through 
enhanced activation of JNK1-3.
35,36
 Inhibition of MEK1/2 and PI3K enhanced MDA-7/IL-
24–induced JNK1-3 activation that was causal in promoting cell killing. Whereas, 
combined inhibition of MEK1/2 and PI3K and mTOR did not lead to a further activation 
of the JNK pathway. Despite this finding, inhibition of the JNK pathway in vitro 
suppressed the toxicity of MEK1/2, PI3K and mTOR inhibition when combined with 
Ad.5-mda-7. Ad.5-cmv infected GBM cells lacking MEK1/2, PI3K, mTOR, and JNK 
signaling did not grow in vitro and did not form tumors in vivo. Thus, the relative role of 
JNK signaling in vivo with respect to Ad.5-mda-7 effects could not be determined.  It has 
been known for a number of years that JNK pathway signaling in GBM cells can promote 
cell killing as well as being essential for their proliferation.44  
Although inhibition of mTOR function modestly enhanced Ad.5-mda-7 lethality in 
vitro, this manipulation did not significantly alter tumor growth in vivo, in contrast to si-
mTOR/dnMEK/dn-p85 expression. The lack of an in vivo effect after inhibition of mTOR 
upon MDA-7 toxicity likely reflects the fact that loss of only mTOR function in vivo may 
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not significantly impact on the long-term tumor-forming ability of GBM cells. It is also in 
general agreement with many observations over decades in which drug combination effect 
in vitro does not fully translate into an animal model system. Hence, inhibition of the 
primary Ad.5-mda-7-dependent “pro-death” JNK pathway signal could suppress all of the 
toxic responses emanating from expression of MDA-7/IL-24 in GBM cells. 
Infection of cells with Ad.5-mda-7 decreased the expression of BCL-XL and MCL-
1, which we have previously demonstrated with GST-MDA-7 to be due to ER stress 
signaling via PERK-eIF2α.35,36,134 One pronounced effect of inhibiting the protective 
signaling pathways was to facilitate MDA-7/IL-24–induced reduction in the expression of 
multiple mitochondrial protective proteins, and over-expression of either BCL-XL or 
MCL-1 maintained tumor cell viability. In studies parallel to those in this thesis MDA-
7/IL-24 induced JNK pathway signaling has been shown to mediate activation of the pro-
apoptotic proteins BAX and BAK. Thus, the MDA-7/IL-24 induced ratio change of pro to 
anti-apoptotic proteins is exacerbated by inhibiting protective signaling pathways, leading 
to greater levels of tumor cell death. 
Prior studies have demonstrated that GST-MDA-7 lethality in GBM cells required 
the induction of a toxic form of autophagy and that autophagy was dependent on PERK 
signaling.
35,37
 Treatment of cells with inhibitors of PI3K/mTOR has been shown in many 
cell systems to enhance autophagy and we noted that inhibition of protective signaling 
pathways enhanced the numbers of autophagic vesicles per GBM cell and enhanced MDA-
7/IL-24–induced autophagy.149 However, this did not correlate with enhanced PERK 
phosphorylation, arguing that the signaling pathways are acting to modulate autophagy at a 
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downstream point, e.g., ATG1/ATG13.
150
 Knockdown of ATG5 or Beclin1 suppressed and 
reduced MDA-7/IL-24 toxicity, but did not abolish the death-inducing effects of the small 
molecule kinase inhibitors.  Collectively, our data argue that inhibition of protective 
signaling pathways promotes MDA-7/IL-24 toxicity via increased JNK signaling, by 
decreased expression of BCL-XL and MCL-1 and by increasing levels of autophagy. 
Temozolomide-based chemotherapy is a mainstay of GBM treatment.1 MDA-7/IL-
24 and temozolomide interacted in a greater than additive fashion to kill GBM cells and 
this effect was increased in at least an additive fashion by exposure to ionizing radiation. 
Temozolomide interacts with DNA inducing a wide spectrum of methyl adducts, e.g., 
methyl-purines.
151
 Temozolomide anti-tumor activity has been predominantly linked to the 
generation of O(6)-methyl-guanine, particularly as tumor cell sensitivity to the drug 
inversely correlates with the expression levels of O(6)-alkyl-guanine DNA alkyl-
transferase and also requires intact mismatch DNA repair. We have recently shown that 
MDA-7/IL-24 toxicity is dependent on the generation of ceramide
134,152
 and it has been 
shown that (i) DNA damage via ATM signaling increases ceramide levels and (ii) that 
temozolomide toxicity is enhanced by agents that block sphingosine kinase activity that 
will de facto increase ceramide levels.
153
 Future studies beyond the scope of this thesis will 
be needed to define the molecular mechanisms by which temozolomide and MDA-7/IL-24 
interact in promoting toxicity in GBM cells.   
GBM was one of the earliest malignancies considered amenable to viral delivery of 
genetic-based therapeutics.139 Serotype 5 human adenoviruses bind to and infect human 
cells through the CAR, a protein whose expression has been shown in several studies to be 
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significantly reduced in primary human GBM cells in culture and in situ. 
139
 Thus, delivery 
of therapeutic genes by this method to GBM cells was originally and unknowingly, 
hampered by the relative inefficiency of this gene delivery method. Multiple groups are 
attempting to solve the relative inefficiency of serotype 5 adenovirus infections in human 
GBM by modifying specific sequences within virus capsid proteins that directly associate 
with CAR, i.e., they are applying targeting strategies to enhance viral infectivity via CAR 
independent pathways. Initial work from several groups involved modification of the 
infective viral capsid “knob” to bind instead to surface integrin proteins whose expression 
is enhanced upon transformation (RGD modification), or by insertion into the knob of 
multiple lysine residues (pK7), which will increase viral interaction with cells by 
electrostatic effects on the cell’s surface. Subsequently, more subtle modifications to the 
proteins expressed as part of the viral capsid knob have been made with the development 
of viruses expressing chimeric knobs containing components of different serotype viruses. 
For example, in some of these viruses the infective capsid knobs from serotype 3 
adenoviruses were incorporated into the adenovirus type 5 knob. The studies in this thesis 
demonstrated that modified serotype 5/3 knob adenoviruses
136,137
 are able to achieve 
enhanced gene transduction into low-CAR (and higher-CAR) containing human GBM 
tumor cells in vitro and in vivo. We also noted that a serotype 5/3 virus was more efficient 
at transducing genes into GBM cells than either an RGD/double RGD modification or a 
pK7 modification.
140
 However, an additional problem of efficacy, exists for all gene 
therapy approaches and one that is exacerbated by the highly invasive and diffuse nature of 
GBM compared to other tumor cell types.1 This problem highlights the need for 
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development of a toxic “bystander” effect in tumor cells that have not been infected by 
virus during the primary infection process. Using the rules of simple mass-action, i.e., the 
total number of non-transformed cells within and around a GBM tumor compared to the 
total number of transformed cells in a tumor to the total number of virus particles being 
infused, it is not possible for all tumor cells in a highly invasive tumor cell type such as 
GBM to be infected by a nonreplicative, and in all likelihood even a conditionally 
replicative adenovirus. Furthermore, many prior studies in GBM using gene therapeutic 
tools have often expressed intracellular proteins that are not normally secreted, which will 
frequently result in only those cells that have been virally infected being subjected to the 
actions of the therapeutic gene.  
The expression of MDA-7/IL-24 overcomes the problems associated with a lack of 
a “bystander” effect following gene therapeutic intervention.14-18,40,138,141 MDA-7/IL-24 is 
secreted from infected GBM cells and as we have demonstrated in GBM,
141
 media 
containing secreted MDA-7/IL-24 can induce apoptosis in uninfected GBM cells.  The 
data in this thesis demonstrates that a type 5/3 recombinant adenovirus was more 
efficacious at delivering mda-7/IL-24 to GBM cells than a type 5 virus, resulting in 
considerably higher expression of MDA-7/IL-24 protein. The greater expression of MDA-
7/IL-24 using the serotype 5 / serotype 3 virus resulted in a greater amount of tumor cell 
killing. However, it is worthy of note, that although infection using Ad.5/3-mda-7 in vitro 
generated at least ~10-fold more MDA-7/IL-24 protein, it only reduced colony 
formation/survival approximately threefold more than Ad.5-mda-7 infection. This argues 
that there may be a threshold at which expression of MDA-7/IL-24 becomes toxic to a 
149 
tumor cell and producing more MDA-7/IL-24 protein will not per se increase killing, at 
least in in vitro assays. The in vivo observations using Ad.5-mda-7 and Ad.5/3-mda-7 
provide a more convincing demonstration of the enhanced effectiveness of using a serotype 
5/3 virus over a serotype 5 virus. At 14 days after Ad.5-mda-7 infection, tumors begin to 
exhibit a modest level of re-growth but Ad.5/3-mda-7 tumors maintain a non-proliferative 
phenotype. These significant findings suggest that Ad.5/3-mda-7 may provide enhanced 
clinical benefit in the context of GBM; validation of which will be attempted in future 
work. 
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CHAPTER 9: CONCLUSIONS 
 
In conclusion, the data in this work demonstrates that MDA-7/IL-24 interacts with 
OSU-03012 to enhance killing of primary human GBM cells in a greater than additive 
manner. The data also indicates that the use of two (or more) agents, that act to increase the 
autophagic response, will further facilitate GBM cell apoptosis. Furthermore, the inhibition 
of two or more survival signal transduction pathways is likely required to promote any 
additional MDA-7/IL-24 toxicity in GBM cells; an effect that is mediated by increased 
mitochondrial instability.  Additionally, combining MDA-7/IL-24 with temozolomide and 
radiation increases MDA-7/IL-24 toxicity versus treatment with either agent alone. The 
data presented here also suggests that the serotype 5/3 viral delivery mechanism may 
provide a means of more effectively translating MDA-7/IL-24 therapy from the bench into 
the clinic for GBM. Based upon the results described in this thesis, future studies that 
target multiple protective signaling pathways in combination with enhanced delivery of 
MDA-7/IL-24 appear warranted. 
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